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Acute and chronic lung injuries remain significant clinical problems, and are the third leading 
cause of death in the United States [1]. Carbon dioxide removal (CO2R) devices can effectively 
manage acute hypercapnia in patients during treatment of acute exacerbations of chronic 
obstructive pulmonary disease (aeCOPD) and acute respiratory distress syndrome (ARDS) when 
combined with protective ventilation strategies [2–4]. Widespread adaptation of CO2R systems 
for this purpose or early intervention have been hindered partially due to invasive placement of 
large diameter intravascular devices or high circuit blood flows necessary for available 
extracorporeal CO2R (ECCO2R) devices. We are in development of mechanical and enzymatic 
approaches that facilitate high efficiency CO2 removal in artificial lung devices to minimize 
invasiveness of treatment with no or low blood flow outside the body.   
The impeller percutaneous respiratory assist catheter (IPRAC) uses an array of rotating 
impellers in an annular bundle to generate an “active mixing” effect that enabled the highest 
efficiency CO2R of any reported artificial lung device [5]. We investigated additional impeller 
design parameters finding gas exchange could be significantly improved by reducing impeller 
axial spacing. Total gas exchange in the IPRAC was improved by 10% versus previous work.   
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 v 
The impeller system was adapted for extracorporeal use in the ultra-low-flow ECCO2R 
device (ULFED) with the objective of matching blood flow rates common for renal hemodialysis 
(250 mL/min). Effective CO2R at ultra-low-flows enables adaptation of common renal 
hemodialysis connection strategies with potential for use with dialysis equipment or to be spliced 
directly in existing dialysis circuitry. CO2 removal up to 75 mL/min (30-37% metabolic CO2 
production) at hemodialysis blood flows was demonstrated in the ULFED. The effects of bundle 
aspect ratio and impeller length on gas exchange were evaluated. Reducing bundle diameter was 
found to improve CO2 removal performance, while bundle and impeller length insignificantly 
affected performance. Subsequent in vitro hemolysis testing showed the ULFED to be 
comparable to a control circuit, indicating no hemolysis related issues are anticipated in vivo. 
Carbonic anhydrase (CA) enzyme fiber coatings were also evaluated for CO2R 
enhancement. CA fibers previously demonstrating 37% improved performance with specific 
applications at ultra-low blood flows [6–8]. Mini-ULFED prototypes were fabricated but did not 
significantly outperform control fibers in gas exchange testing versus active mixing alone.  
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𝑎 Reynolds coefficient 
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 CO2 solubility in blood, mLCO2/mL/mmHg 
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1.0 INTRODUCTION 
Lung disease remains a global concern and is the third leading cause of death in the United 
States, responsible for 147,000 deaths annually [9]. Treatment typically consists of invasive 
mechanical ventilation (IMV) where patients are intubated and sedated, and can further 
exacerbate lung injuries due to high tidal volumes and inspiratory pressures. Alternative 
treatments utilize membrane gas exchangers that perform respiratory function independent of the 
lungs, allowing the injured tissue to rest and heal. Emerging technologies have improved 
efficiency and effectiveness of this approach and show promise to minimize the need for IMV. 
This chapter describes both approaches as well as two prevalent forms of lung disease that 
motivated work in this field, Chronic Obstructive Pulmonary Disease (COPD) and Acute 
Respiratory Distress Syndrome (ARDS). The objective of this project was to develop previously 
unexplored approaches for highly efficient CO2 removal in an intravascular or extracorporeal 
device that enables minimally invasive partial respiratory assistance and treatment of acute 
hypercapnic respiratory failure. The basic principles of artificial lung technology and overall 
goals of this work are also described in this chapter.  
 2 
1.1 RESPIRATORY DISEASES 
Chronic forms of lung failure such as chronic obstructive pulmonary disease (COPD) currently 
afflict an estimated 23.6 million Americans [10]. COPD is a group of respiratory conditions 
including chronic bronchitis (bronchiole inflammation) and emphysema (deterioration of 
alveolar elasticity), characterized by dyspnea, lung airflow limitations, coughing, and other 
symptoms [11]. The condition is diagnosed in 80-90% of cases due to smoking related airway 
injuries, but environmental and genetic factors such as exposure to air pollution, second-hand 
smoke, and occupational dust and chemicals can also lead to COPD [12]. The economic burden 
of COPD in the United States is considerable, costing an estimated $43 billion in direct and 
indirect costs in 2007 [10]. Less severe cases can be treated with pharmacotherapies to manage 
symptoms, but this approach has not been shown to modify the long-term decline of lung 
function, and patient adherence to prescribed therapy is low [10]. 
Acute exacerbations of COPD (aeCOPD) can onset from bacterial exposure, viral 
infection, or exposure to pollution [13]. Defined as a change in a patient’s “baseline dyspnea, 
cough, and/or sputum that is beyond day-to-day variations, is acute in onset, and may warrant a 
change in regular medication in a patient with underlying COPD", aeCOPD hospitalizes over 
725,000 patients annually, with a mortality rate of 10-25% [14]. aeCOPD can normally be 
treated with antibiotics and corticosteroids for mild exacerbations, but in the 15–25% of cases 
associated with moderate-to-severe respiratory acidosis (pH < 7.25 and/or PaCO2 > 45 mmHg) 
patients are often transitioned to invasive mechanical ventilation (IMV) [14]. IMV requires 
patients to be sedated and intubated to allow forced respiration using high tidal volumes (~12 
mL/kg) and plateau pressures (Pplat >30 cmH20) [15]. Outcomes using IMV demonstrate benefit 
versus no treatment, however the aggressive volumes and pressures necessary for full respiratory 
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support introduce a risk of barotrauma and volutrauma [15]. High pressures risk epithelial and 
endothelial injury with subsequent pulmonary edema and protein leakage, while high tidal 
volumes can cause over-distension and rupture of alveolar tissue [15]. The risk of ventilator-
induced lung injuries (VILI) can be alleviated by reducing vent settings, but this may reintroduce 
hypercapnia and blood acidosis, and complicates weaning from ventilation. Recent work has 
demonstrated aeCOPD patients can benefit from non-invasive ventilation (NIV), where 
intubation is avoided by using a facial mask for respiration [14]. NIV has become the standard of 
care in severe exacerbations of COPD versus traditional IMV, reducing mortality rates from 23% 
to 9% [16, 17]. 15–26% of patients still fail NIV and are transitioned to IMV however, where 
mortality rates are greater than if the patient had initially been treated with IMV [16, 18–21]. 
Common indications of NIV failure are hypercapnia, severe acidosis, dyspnea, and increased 
respiratory rate – all manifestations of inadequate CO2 management [22]. The issues associated 
with hypercapnia during ventilation in severe ae-COPD demonstrate a need for additional 
management of blood CO2 in patients during NIV to prevent intubation, and during IMV to 
improve weaning.  
An acute form of respiratory failure, ARDS, is the result of pulmonary inflammation in 
response to direct or indirect insult and has mortality rates between 40-45%, afflicting around 
190,000 patients annually [23–25]. ARDS is characterized by a breakdown of the alveolar-
capillary barrier leading to the flooding of alveolar sacs and a dramatic reduction in gas 
exchange effectiveness as resistance to gas diffusion in the fluid filled sac increases [26]. ARDS 
is clinically indicated as severe hypoxemia that is rapid onset, with radiographic evidence of 
bilateral pulmonary infiltration, the absence of left heart failure, and is generally diagnosed in 
patients already critically ill from shock, pneumonia, sepsis, or other trauma [24, 27]. Death 
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usually results from widespread hypoxemia and multi-organ failure rather than lung failure alone 
[24]. IMV is the traditional approach for ARDS therapy, but the ARDSnet studies demonstrated 
patients can benefit from lung-protective ventilation (LPV) using lower tidal volumes (VT = 6 
mL/kg) and plateau pressures (Pplat <30 cmH2O) [28]. These recommendations demonstrated a 
reduction in mortality rates by 22% versus traditional IMV settings (VT = 12 mL/kg), however, 
more recent studies have shown that patients are still at risk of VILI [28, 29]. The reduced 
mortality rates were shown to be linearly related to VT and Pplat settings, leaving several to 
postulate that further reduction of these settings may improve outcomes (ultra-protective lung 
ventilation, ULPV: VT = 4 mL/kg, Pplat ≤ 25 cmH2O) [30]. Avoidance of injury using this 
approach can sufficiently oxygenate patients but CO2 removal requires higher tidal volumes. 
This introduces serious risks of inducing hypercapnia with subsequent respiratory acidosis and 
related injuries [23]. As with aeCOPD, newer ventilation techniques are beneficial for ARDS 
treatment, but CO2 removal remains a challenge that if left unmanaged can negate the benefits of 
newer treatments. The clinical need for additional means of mitigating respiratory acidosis in 
these two patient populations are among the primary motivations behind the development of CO2 
removal devices as well as this project. 
1.2 ARTIFICIAL LUNGS FOR CO2 REMOVAL 
Gas exchange specifically targeting CO2 removal was conceptualized by Kolobow and Gattinoni 
in the late 1970’s. They demonstrated in lambs that if a portion of the metabolic CO2 production 
could be eliminated during IMV by alternative means, vent settings could be modified to reduce 
tidal volumes, peak inspiratory pressure, and respiratory rate [31, 32]. The basic principles of 
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operation of CO2 removal devices are shared with extracorporeal membrane oxygenation 
(ECMO). The key advantage for CO2 removal devices is that a significant volume of CO2 is 
present in relatively small volumes of blood, and extracorporeal CO2 removal (ECCO2R) 
treatment can be effective at comparatively lower blood flow rates. CO2 is predominantly carried 
in the form of highly soluble bicarbonate ion that rapidly restores depleting CO2 as it is 
eliminated, and the CO2 dissociation curve is essentially linear and does not saturate like the 
oxyhemoglobin dissociation curve [31, 33, 34].  The full metabolic production of CO2 (200 
mL/min) is contained in approximately 400 mL of blood, meaning that an artificial lung can 
theoretically fully support CO2 removal needs at blood flow rates ~10% of that necessary for 
equivalent oxygenation support (4-7 L/min) [35, 36]. While ECMO systems could be jointly 
utilized for CO2 removal, the differences in exchange dynamics and the benefits CO2 
management alone can provide, there is significant potential and need for the development of 
minimally invasive systems specific to this application.  
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Figure 1.1. Artificial Lung Device. Medtronic Affinity artificial lung cartridge showing common 
elements of oxygenator devices. 
 
1.2.1 Gas Exchange Dynamics in Hollow Fiber Membranes 
Modern artificial lung devices are primarily built on the same basic concept of gas exchange via 
partial pressure differences across a packed bed of microporous hollow fiber membranes 
(HFMs). This concept has been implemented in various ways to maximize efficiency, minimize 
invasiveness, and reduce complexity with the development of extracorporeal [37–40], 
intravascular [5, 41–46], and paracorporeal [47–49] artificial lung devices. Extracorporeal 
designs (Figure 1.1) are largely derived from cardiopulmonary bypass (CPB) systems and consist 
of a flow-through cartridge containing a large bundle of hollow fiber membranes. Blood passes 
over membranes outside of fibers, and gas exchange occurs through the fiber wall. A sweep gas, 
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often pure O2, flows through hollow fiber membrane lumens, creating a partial pressure gradient 
between gas levels in the blood and sweep gas that facilitates diffusion across the fiber wall. 
Fibers have microporous walls and are fabricated from hydrophobic polymers such as 
polypropylene (PP) and modern polymethylpentene (PMP) making them permeable to gasses, 
but impermeable to fluids [50]. This material property enables effective separation of gas and 
blood pathways. Both O2 and CO2 diffuse across the membrane wall based on a differential 
gradient, where O2 moves into the blood with a strong gradient (pO2
𝑔𝑎𝑠: pO2
𝑏𝑙𝑜𝑜𝑑 ≈ 700:45 
mmHg) and CO2 exits the blood into the sweep gas down a weaker gradient (pCO2
𝑔𝑎𝑠: pCO2
𝑏𝑙𝑜𝑜𝑑 
≈  50:0 mmHg). Once in blood the majority of O2 binds to hemoglobin within red cells, which 
quickly become saturated (inlet → outlet saturation ≈ 65 → 100%). In contrast the majority of 
CO2 in blood is in the form of bicarbonate ion (HCO3), which dramatically increases the carrying 
capacity of CO2 in blood, but maintains pCO2 at relatively low levels making decarbonation 
challenging. As a result of the high carrying capacity the exchange rate of CO2 is largely 
independent of blood flow rate and can be achieved at significantly lower flow rates (<500 
mL/min) than those needed for oxygenation. 
 
 
 
 
Figure 1.2. Gas exchange between blood and sweep gas across HFM wall. 
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Gas exchange rate is also largely dependent on diffusive resistances of gasses in fluid. 
The overall mass transfer rate is ?̇?𝐶𝑂2 = 𝐾𝐶𝑂2𝐴𝑓(𝑝𝐶𝑂2,𝑔 − 𝑝𝐶𝑂2,𝑏) where 𝐾𝐶𝑂2 is the CO2 
permeance, 𝐴𝑓 is the fiber membrane surface area, and 𝑝𝐶𝑂2,𝑔 and 𝑝𝐶𝑂2,𝑏 are the CO2 partial 
pressures in the sweep gas and blood, respectively. Gas permeance is dictated by the diffusive 
resistances in the sweep gas pathway, through the membrane wall, and through blood [50]. 
Transfer resistance within the sweep gas pathway itself is negligible, so the permeance is 
primarily dependent on blood-side resistance and to a lesser extent the membrane resistance. 
Blood-side resistance is a function of the diffusional boundary layer thickness that exists on the 
gas exchange surface, where fluid velocity is reduced by drag forces. Within the boundary layer 
molecular diffusion dominates in contrast to convection that occurs in bulk flow. The overall rate 
of gas transfer is therefore limited by the diffusional distance necessary to traverse the surface 
boundary layer. CO2 near the fiber surface within the boundary layer is quickly eliminated but 
the majority of additional CO2 comes from bulk flow, requiring it to first diffuse the full 
thickness of the boundary layer to reach the fiber surface. Most modern artificial lungs take 
advantage of cross-flow fiber orientations rather than parallel orientations, which to an extent 
reduces development of the surface boundary layer [50, 51]. A more effective means of reducing 
the fiber boundary layer thickness is by increasing fluid velocity, which directly impacts the 
boundary layer and improves gas exchange efficiency. Several devices previously developed and 
in use utilize this approach to enhance performance by mechanically agitating blood near fibers 
to increase fluid velocity, creating an "active mixing" effect that will be expanded on in the 
following section and Chapter 2. A more detailed analysis of the equations and factors governing 
CO2 transfer rates are also presented in Section 5.2.4. 
 9 
1.3 INTRAVASCULAR CO2 REMOVAL DEVICES 
Carbon dioxide removal devices have been developed for intravascular and extracorporeal use. 
Intravascular devices, or respiratory assist catheters, are intended for percutaneous insertion into 
the inferior vena cava and generally consist of a long slender fiber bundle. The primary 
advantage of this approach is that it eliminates the complexity and concerns associated with 
traditional extracorporeal circuits. A device without blood circuitry obviates use of a blood 
pump, reduces blood-contacting surface area, simplifies device management, and avoids fluid 
loading patients with a primed circuit during device connection/insertion. An intravascular also 
exposes the device to the majority of the cardiac output (≈2/3), minimizing potential for flow rate 
limited gas exchange observed in low-flow ECCO2R devices.  
The major challenge in development of intravascular devices is removing enough CO2 
with a form factor compact enough to function in the vasculature [52]. CO2 removal of 70-160 
mL/min has been shown to benefit patients with hypercapnia, which translates to a target CO2 
removal rate of ≥25-35% metabolic CO2 production (~200-250 mL/min) at normocapnia (pCO2 
= 45 mmHg) [53, 54]. This level of gas exchange is challenging with small surface areas so most 
research in this area has focused on development of approaches that increase gas exchange 
efficiency. The first successful design was the Intravenous Oxygenator (IVOX), which to date is 
the only catheter device tested in humans [42, 55]. The IVOX used crimped fibers to disturb 
blood flow pathways and avoid fiber clumping in the vena cava, and achieved CO2 removal rates 
up to 40–70 mL/min [56]. Approximately 30% of patients showed improvements in blood gasses 
such that ventilator settings could be reduced, however performance levels were deemed 
insufficient and clinical trials were halted [42]. Additional concerns surrounding the large 
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insertion size of the IVOX (34–50 Fr) that required a specialized surgeon for placement 
ultimately suspended further developments [57, 58].  
Later respiratory assist catheters focused on improving overall gas exchange and 
reducing insertion size using novel approaches to maximize efficiency. The Hattler Catheter 
shown in Figure 1.3 uses a pulsating balloon inside an annular fiber bundle to generate an "active 
mixing" effect that increases flow velocity through the bundle [59]. Greater velocity and bundle 
cross-flow diminish the highly limiting diffusive boundary layer at the gas exchange surface, 
facilitating maintenance of stronger gaseous concentration gradients spanning fiber walls and 
increasing transfer efficiency. Active mixing improved gas transfer in the Hattler Catheter to 
levels 50–300% greater than non-pulsating devices [60]. Despite promising performance the 
large insertion size of the Hattler Catheter (32 Fr) ultimately limited clinical appeal and 
development was suspended.  
 
 
 
 
Figure 1.3. Hattler Catheter & IPRAC Respiratory Assist Catheters. Cutaway fiber sections 
showing indwelling balloon (Hattler Catheter, bottom) and rotating impellers inside safety coil 
(IPRAC, top). 
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The majority of other reported designs used novel fiber arrangements and mechanical 
mechanisms to enhance performance but were unable to achieve clinically relevant levels of total 
gas exchange. Notable examples are the PENSIL, which used pressure cycling in closed-end 
fibers [43, 61], the D-ILAD that arranged fibers in a rotating Archimedes screw [44], the 
HIMOX using fibers in an expanding disk-shaped configuration [45, 62], and the IVLAD with 
fibers wrapped over a vibrating actuator to impose active mixing [46]. 
1.3.1 The Impeller Percutaneous Respiratory Assist Catheter (IPRAC) 
The most recent development in this area and one primary focus of this project is the Impeller 
Percutaneous Respiratory Assist Catheter (IPRAC) in development in our lab (Figure 1.3). The 
IPRAC consists of a slender HFM bundle surrounding an array of rotating impellers that 
generate highly effective active mixing [5]. CO2 removal rates up to 529 mL/min/m
2 were 
achieved (39 mL/min total) on the bench, the highest efficiency of any reported gas exchanger. 
Previous work focused primarily on characterizing the relationship between rotation rate and gas 
exchange, as well as evaluation of various impeller geometries. In these studies a strong 
relationship between impeller design and gas exchange was observed, suggesting further 
improvements could be made to increase IPRAC performance. The existing design has an 
insertion diameter of 25 Fr, which we believe can be reduced by improving total CO2 removal 
rates through investigation of new impeller designs and implementation of carbonic anhydrase 
(CA) immobilized HFMs. This bioactive fiber approach was shown to improve CO2 removal 
rates by up to 36% in blood by facilitating the conversion of bicarbonate ions to CO2 within the 
fiber boundary layer [7]. Chapter 6.0focuses on the combination of these technologies. 
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The primary objective of this project is to improve upon existing technologies to develop 
minimally invasive CO2 removal devices. The design objectives for a respiratory assist catheter 
are:  
1. CO2 removal rates equivalent to 25-35% of the metabolic CO2 production (≥65 mL/min) at 
normocapnia (pCO2 ≈ 45 mmHg).  
2. Minimally invasive insertion diameter (< 20 Fr).  
3. In vitro hemolysis levels comparable to a gas exchange circuit of commercially available 
components.  
1.4 EXTRACORPOREAL CO2 REMOVAL DEVICES (ECCO2R) 
CO2 removal devices were initially conceptualized as extracorporeal systems and the most 
progress has been in this area. Three general approaches for extracorporeal CO2 removal 
(ECCO2R) have been explored – arteriovenous CO2 removal (AVCO2R), venovenous CO2 
removal (VVCO2R), and low-flow systems intended for compatibility with CRRT (continuous 
renal replacement therapy) circuits. Several technologies for enhancing performance efficiency 
have also been utilized that could potentially be integrated within any of these systems including 
active mixing, bioactive fibers, blood acidification, and electrodialysis.  
1.4.1 Arteriovenous CO2 Removal (AVCO2R) 
The most commonly used configuration of ECCO2R is with arteriovenous cannulation. AVCO2R 
uses a low-resistance oxygenator (Novalung iLA) in a circuit generally bridging the femoral 
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artery and vein [63]. The arteriovenous pressure differential drives flow through the circuit, 
eliminating the need for a blood pump. At flow rates up to 1.5 L/min, CO2 removal rates of 100–
200 mL/min were reported in acute animal models of ARDS [49, 64, 65]. In a clinical report 
AVCO2R was shown to help avoid intubation for IMV in 19 of 21 patients (10% intubation rate, 
versus 100% in the control arm), however there was no difference in long-term mortality rates 
[66]. There are several limitations associated with AVCO2R however. Circuit flow is dependent 
on cardiac output and therefore any peripheral vascular disease or decompensated heart failure 
are contraindications for use [67]. Cannulation also risks ischemia and limits ambulation, 
promoting patient deconditioning [53]. The large bore, dual cannulation required to sustain the 
high blood flows has also limited clinical appeal of AVCO2R for early intervention, a 
shortcoming that has become a focal area for improvement with newer technologies. 
1.4.2 Venovenous ECCO2R (VVCO2R) 
Recent developments in ECCO2R have focused on addressing the limitations of AVCO2R. New 
ECCO2R systems incorporate a blood pump that eliminates the cardiac-related contraindications 
and enables single-site venovenous cannulation, and can operate at lower blood flows (≤500 
mL/min) to allow the use of smaller bore cannula. The Hemolung Respiratory Assist System 
(RAS) from ALung Technologies is an integrated pump-oxygenator that uses a 15.5 Fr dual-
lumen cannula for patient connection [22]. A rotating smooth-walled cylindrical core adjacent to 
gas exchange fibers generates secondary flows within the HFM bundle (0.59 m2), making it the 
only approved device that incorporates a mechanism specifically for active mixing. This feature 
increases in vitro CO2 removal by up to 60%, generates significant washing to minimize 
thrombus formation and reduces fiber surface area required for respiratory support [68]. The 
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Hemolung has been reported in several case studies to be an effective co-therapy to NIV for 
patients with aeCOPD as a means to avoid intubation or aid weaning from IMV [3, 4, 69, 70]. In 
15 patients with moderate ARDS the Hemolung was used to regulate PaCO2 and pH during 
UPLV (VT = 4 mL/kg) with minimal complications, and will be included in the upcoming 
SUPERNOVA (A Strategy of UltraProtective lung ventilation With Extracorporeal CO2 
Removal for New-Onset moderate to seVere ARDS) trials for assessment of ECCO2R to 
facilitate UPLV in moderate to severe ARDS [23].  
Novalung’s iLA Activve system includes a central controller with compatibility for 
several passive gas exchange cartridges for a range of blood flow rates ranging from low-flow 
ECCO2R to ECMO. Using the "mid-flow" cartridge (1.3 m
2 iLA Membrane Oxygenator also 
used in AVCO2R) and 22 Fr cannula, CO2 removal rates <50 mL/min were observed at a blood 
flow of 0.5 L/min in 10 hypercapnic patients [71]. In controlled clinical trials (ECLAIR), 
intubation was avoided in 14/25 patients (56%) with acute hypercapnic respiratory failure 
refractory to NIV, however major bleeding was observed in 36% of patients in addition to other 
major complications associated with the device including extracorporeal clotting and air 
detection in the circuit [72]. The “low-flow” iLA Activve kit uses a cylindrical bundle design 
(0.35 m2) and is intended for blood flows ≤ 800 mL/min using an 18 Fr dual lumen cannula for 
venous access, but data available for this configuration is limited.  
1.4.3 Low-Flow ECCO2R 
Developing ECCO2R systems primarily direct focus on further reducing necessary blood flow 
rates for venovenous treatment to 200-400 mL/min. The Hemodec DECAPsmart uses a pediatric 
membrane lung (0.3 m2) in series with a polysulfone hemofilter (1.35 m2) to operate at low blood 
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flows (<500 mL/min) [73]. Plasma is pulled out of blood in the hemofilter and then recirculated 
back to an oxygenator. Plasma recirculation increases the flow rate through the oxygenator 
thereby improving gas transfer efficiency by means similar to active mixing, i.e. increased blood 
velocity at the fiber surface to reduce the diffusive boundary layer thickness. The DECAPsmart 
was successfully used in adults and children before the design was acquired, becoming the Estor 
ProLUNG [74–76]. The oxygenator has since been replaced with a larger surface area device 
(1.8 m2) and the novel plasma recirculation component was eliminated, reducing the complexity 
of the system. In a small study using the modified design, intubation was avoided in 88% of 
patients on NIV and ECCO2R with acute hypercapnic respiratory failure associated with 
aeCOPD versus 66% avoidance with NIV alone, however this difference was not statistically 
significant and complication rates were high (51% of patients, primarily due to device 
malfunction) [77]. Maquet also began development of the PALP CO2 removal system that could 
operate at flows down to 0.2 L/min using a 0.98 m2 gas exchanger cartridge for use with their 
CARDIOHELP system [78]. Average CO2 removal rates of ~60 mL/min were reported at these 
flows in hypercapnic pigs, however planned aeCOPD clinical trials were canceled prior to 
enrollment [78, 79].  
The PrismaLung system was the first artificial lung to be designed specifically as an 
attachment to existing hemodialysis hardware. The system consists of a Medos Hilite 800 LT 
pediatric oxygenator (0.32 m2) fitted to a Gambro-Baxter Primaflex hemodialysis controller with 
13 Fr dual lumen dialysis cannula. Performance was evaluated in hypercapnic pigs (PaCO2 > 80 
mmHg) with modest removal rates ≤60 mL/min at blood flow rates of 400 mL/min [80]. PaCO2 
levels were reduced but not returned to normal levels (81 mmHg to 70 mmHg). At low flows 
(200–300 mL/min) CO2 removal rates were lower (40–55 mL/min). The benefit to patients at 
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these low performance points will be assessed in upcoming human trials with the PrismaLung for 
use with CRRT hardware [81] and as UPLV co-therapy for mild–moderate ARDS [82] and 
severe ARDS [83]. 
1.4.4 Approaches for Enhancing CO2 Removal 
Several alternative approached to enhance CO2 removal efficiency have been explored to reduce 
flow rates necessary for clinically significant gas exchange. Bioactive fibers that have carbonic 
anhydrase (CA) enzyme immobilized on gas exchange surfaces locally convert bicarbonate ion 
to CO2 at the fiber surface [7, 8]. CO2 removal rates improved up to 37% using CA fibers in 
blood versus untreated control fibers in miniaturized artificial lung modules [84]. Disruption of 
the diffusive boundary layer in an active mixing system may also improve enhancement 
associated with CA fibers, which is investigated in Chapter 6.0. CA fiber performance can also 
be improved by adding small amounts of acidic sulfur dioxide (SO2) gas to fiber sweep gas [85]. 
Diffusion of acidic species directly into the surface boundary layer increases local pCO2 by 
promoting the conversion of bicarbonate ion to CO2 at the gas exchange surface. This increases 
the partial pressure driving gradient across fiber walls and improves CO2 removal. Acid gas 
alone enhanced gas exchange by 17%, but worked synergistically with CA fibers to increase CO2 
removal by 109% in miniaturized artificial lung modules. Whole blood acidification has also 
been investigated with infusion of lactic acid to an ECCO2R circuit [86, 87]. CO2 removal rates 
improved up to 78% during 48 hour studies in pigs with no indications of significant organ or 
erythrocyte damage. Electrodialysis has been explored to modulate blood electrolyte 
concentrations to promote bicarbonate conversion to CO2 in a gas exchange circuit [88, 89]. CO2 
removal nearly doubled (to 112 mL/min) at low blood flows of 250 mL/min in five acute studies 
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in pigs, but further testing is necessary to assess safety with respect to renal function. 
Bicarbonate dialysis was evaluated in acute sheep studies to eliminate CO2 from blood in the 
form of bicarbonate ion [90]. A hemofilter was used to remove 100-150 mL/min of ultrafiltrate 
from 350-400 mL/min of blood containing CO2 and bicarbonate and replaced with an equal 
volume of sodium hydroxide replacement solution. An average 60 mL/min of CO2 was removed 
from blood at normocapnia without complications.  
Several novel approaches have been explored for enhancing CO2 removal in HFM 
devices that are largely independent of bundle design and could be used to reduce fiber surface 
area, achieve greater overall gas exchange performance, or reduce necessary blood flow rates. 
Active mixing, as described above and later in Chapter 2.0, is an established means of increasing 
CO2 and O2 exchange efficiency and has been implemented in the approved Hemolung VVCO2R 
system as well as the majority of respiratory assist catheters previously developed. This approach 
shows significant promise and is critical to the functionality and effectiveness of each of the 
devices described in this project. Bioactive HFMs have also been investigated to specifically 
improve CO2 removal [6]. Carbonic anhydrase (CA) is an enzyme native to erythrocytes that is 
responsible for catalyzing the reversible reaction that converts CO2 gas to its predominant form 
in blood, bicarbonate ion (HCO3). Immobilization of CA enzyme directly to the fiber surface 
allows depleted CO2 within the boundary layer to be replenished locally from HCO3, rather than 
exclusive reliance on the diffusion of additional CO2 from bulk fluid outside the boundary layer. 
Using this approach CO2 removal from blood was improved by 37% [7, 8]. This approach has 
promise in combination with active mixing as is explored in Chapter 6.0.  
Controlled addition of acidic species to blood has also been shown to improve CO2 
removal rates in artificial lungs by taking advantage of the blood buffering system, which forces 
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conversion of some bicarbonate ion to CO2 in order to regulate pH. This spike in pCO2 increases 
the driving gradient for elimination by hollow fiber membranes. This approach has been 
explored through whole blood acidification using naturally occurring lactic acid [86, 87] and by 
mixing acidic SO2 gas into the fiber sweep gas to introduce acidic species directly at the fiber 
surface [85]. CO2 removal enhancement is promising but these approaches present several 
technical challenges and are still experimental. An approach for decarbonation through 
electrodialysis has been reported as well, where an electrical field is applied to blood to 
selectively modulate pH and electrolyte concentrations [88]. CO2 removal rates were improved 
by 75% during acute testing in pigs through electrodialysis, however blood electrolyte 
concentrations were affected by the treatment and the approach adds significant complexity to 
the gas exchange circuit.  
1.4.5 Objectives for Minimally Invasive CO2 Removal 
Significant progress in ECCO2R has been made, but improvements are necessary to provide 
simple, safe, effective, and minimally invasive respiratory support at low-blood flow rates. 
Recognizing the potential for advancement in this area, this project also explores the efficacy of 
utilizing the rotating impeller technology from the IPRAC for an extracorporeal device. The 
design objectives for an ECCO2R device are: 
1. CO2 removal rates equivalent to 25-35% of the metabolic CO2 production (≥65 mL/min) at 
normocapnia (pCO2 ≈ 45 mmHg) and dialysis blood flow rates (250 mL/min). 
2. Minimally invasive cannula (< 15 Fr). 
3.  In vitro hemolysis levels comparable to a gas exchange circuit of commercially available 
components.  
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The gas exchange and hemocompatibility objectives for an ECCO2R device are 
comparable to those for a respiratory assist catheter. The target insertion diameter for cannula in 
an external circuit are less than for an intravenous device however, since the increased size is 
considered an appropriate tradeoff for the simplicity and lack of external circuitry with an 
insertable device. 
Our goal is to advance previously explored approaches for highly efficient CO2 removal 
for use in an intravascular or extracorporeal device that enables minimally invasive partial 
respiratory assistance. This thesis describes the continued development of the IPRAC and initial 
design, fabrication, and testing of a new extracorporeal device that utilizes the IPRAC impeller 
technology for minimally invasive ECCO2R. Chapter 2.0 and 3.0 focus on evaluation of new 
IPRAC impeller designs and arrangements on gas exchange and hemocompatibility. To 
investigate the potential for the impeller concept in alternative artificial lung applications, 
Chapter 4.0 presents the results of feasibility experiments for an IPRAC design modified for 
extracorporeal use at ultra-low blood flows, characteristic of renal hemodialysis. Chapter 5.0 
builds on the development of an ultra-low-flow ECCO2R device (ULFED) through redesign of 
the feasibility prototype tailored for extracorporeal use. New design parameters were identified 
and evaluated for in vitro gas exchange and hemolysis. Finally, Chapter 6.0 reports the results of 
feasibility testing of combining mechanical and enzymatic approaches for enhancing CO2 
removal, where CA immobilized fibers are incorporated into an impeller active mixing device.  
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2.0 EFFECT OF IMPELLER DESIGN AND SPACING ON GAS EXCHANGE IN A 
PERCUTANEOUS RESPIRATORY ASSIST CATHETER 
The following chapter presents work peer-reviewed and published in the journal Artificial 
Organs [91]. Computational fluid dynamics (CFD) modeling was conducted by Dr. Greg 
Burgreen, PhD, at the University of Mississippi. Methods, results, and discussion specifically 
pertaining to that work can be found in the above reference. Noteworthy discussion from the 
modeling analysis is included in the sections below. 
2.1 INTRODUCTION 
The benefit of providing partial respiratory support (CO2 removal) for patients with acute 
hypercapnic respiratory failure has been demonstrated with extracorporeal CO2 removal 
(ECCO2R) devices [92, 93]. Similar to extracorporeal membrane oxygenators (ECMO), 
ECCO2R systems utilize microporous hollow fiber membranes (HFMs) to remove CO2 and add 
oxygen (O2) to the blood [94–96]. By these means, ECCO2R performs respiratory function 
independent of the pulmonary system, allowing the injured lungs to rest and heal. Partial 
respiratory support can prevent the need for invasive mechanical ventilatory (IMV) treatment in 
patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) and allows 
low tidal volume lung protective ventilation (LPV) strategies to be utilized in the treatment of 
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acute respiratory distress syndrome (ARDS) [25, 28]. Concerns with ECCO2R are similar to 
those of traditional ECMO however, in that blood loop and equipment management can be 
highly complicated. Some emerging ECCO2R systems are comparatively less complex to operate 
[2, 7], but all still depend on passage of blood through an external flow loop and generally have a 
high surface area of synthetic material directly in contact with blood [97].  
Several groups have previously or are currently investigating the development of an 
intravenous device for partial respiratory support [43, 44, 46, 56, 62, 98]. All of these devices use 
HFMs as in ECMO/ECCO2R, but instead of removing blood from the body in an external circuit, 
intravenous devices are inserted percutaneously into the venous system (generally the inferior 
vena cava, IVC). As a result, intravenous respiratory assist devices also have the advantage of 
performing respiratory function independent of the lungs, allowing the injured pulmonary tissue 
to rest and heal. In contrast to ECMO/ECCO2R however, the complexities associated with blood 
flow loops and circuit management are eliminated along with the high blood-contacting surface 
area. Intravenous devices also do not require a circuit blood pump and have the benefit of 
performing gas exchange on systemic blood flow through the IVC (≈2/3 cardiac output), whereas 
blood availability for gas transfer in extracorporeal devices is limited by circuit blood flow. The 
greatest challenge in development of this technology is achievement of sufficient gas transfer 
with the limited gas exchange surface area that can be incorporated into a device that functions 
within the venous system while minimizing insertion size [97]. Early intravenous devices 
achieved CO2 removal rates up to 40-70 mL/min [99, 100] and reached human clinical trials 
[42], but concern surrounded the large diameters (32-50 Fr), which required specialized surgeons 
for insertion [42, 55, 58]. To eliminate the need for surgical insertion we are seeking to develop 
an intravenous device with an insertion diameter of 20-25 Fr. A promising approach we are 
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investigating to achieve this was first presented by Mihelc et al., which consists of a slender 
HFM bundle surrounding an array of rotating impellers to generate an “active mixing” effect [5]. 
Active mixing improves mass transfer by increasing blood velocity across gas exchange 
surfaces, which diminishes the highly limited diffusive boundary layer at the membrane surface 
and prevents blood-side accumulation of oxygen and depletion of carbon dioxide at the 
membrane surface [101]. This maintenance of a strong gas partial pressure differential across the 
membrane promotes efficient gas exchange. The impeller percutaneous respiratory assist catheter 
(IPRAC) achieved CO2 removal rates up to 529 ± 20 mL/min/m
2 on the bench with a total fiber 
surface area of 0.07 m2, for a total removal rate of 36 mL/min during pilot studies [5]. Earlier 
work focused primarily on characterizing the relationship between rotation rate and gas 
exchange, as well as evaluation of eight different impeller designs. Not surprisingly, gas 
exchange correlated directly with rotation rate, and maximum CO2 removal rates were achieved 
at the highest rate tested (20,000 RPM) [5]. A strong dependence of gas exchange on impeller 
design was also observed. The top performing design achieved exchange rates over twice that of 
the lowest performer. Recognizing the potential for further improvement to gas exchange, the 
objective of this work was to combine bench work and computational fluid dynamics (CFD) to 
develop and evaluate several new impeller designs for the IPRAC. We additionally investigated 
the effects on gas exchange of features such as axial spacing between impellers and number of 
blades.  
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2.2 METHODS 
2.2.1 Device Description 
The IPRAC prototype (Figure 2.1A) consists of an array of impellers fixed to a flexible stainless 
steel driveshaft (0.042” (1.07 mm) diameter) (SS304V, Heraeus Medical Components, St. Paul, 
MN) that rotate concentrically within a stationary stainless steel coil (inner diameter 5 mm). 250 
polypropylene (PP) fibers (x30-240; Membrana Celgard, Wuppertal, Germany) are wrapped 
around the outside of the coil, preventing direct contact between impellers and fibers (Figure 
2.2B). Individual fibers have outer diameters of 300 μm and measure 30 cm in length, for a total 
membrane surface area of 0.07 m2. The flexible driveshaft extends out of the fiber bundle 
through the medial manifold where it connects to an external DC brushless servomotor (2444-
024B; MicroMo Electronics Inc., Clearwater, FL) at the proximal manifold. To prevent backflow 
of fluid up the driveshaft tubing, an infusion line continually pumps fluid at 15 ml/hr down the 
driveshaft tube toward the medial manifold where it exits the device into the recirculating loop.  
The sweep gas pathway in the full IPRAC prototype incorporates both the inlet and outlet gas 
ports in the proximal manifold, permitting percutaneous insertion to the inferior vena cava via 
the femoral vein (Figure 2.1B). Sweep gas enters the inlet port and flows directly into the fiber 
bundle at the medial manifold. Sweep flow exits the fiber bundle in the distal manifold, where it 
enters separate tubing integrated into the fiber bundle that returns it to the gas outlet port in the 
proximal manifold. This return gas pathway consists of wire reinforced polyimide tubing 
(MinVasive Components, Trenton, GA). This design is different from that described by Mihelc 
et al., which used a hollow driveshaft tube to return the sweep gas from the distal to proximal 
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manifold. This modification allows the diameter of the impeller driveshaft to be significantly 
reduced versus previous prototypes. 
 
 
 
 
Figure 2.1. IPRAC and Modified IPRAC prototypes. (A) Full IPRAC prototype with gas inlet 
and outlet at the proximal manifold. (B) Modified IPRAC used for in vitro CO2 removal from 
water with distal manifold sweep gas outlet port and interchangeable impeller driveshaft. 
 
 
 
In this work a modified IPRAC device (Figure 2.1B) was used to evaluate gas exchange 
of each impeller. In vitro testing does not require percutaneous insertion, so the gas pathway was 
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configured to allow sweep gas to exit directly from the distal manifold, thereby eliminating the 
need for return gas pathway tubing. The modification also allowed the impeller driveshaft to be 
easily interchanged. This enabled the use of the same fiber bundle for all testing, thereby 
eliminating a potential source of variability. The sweep gas pressure at the fiber bundle inlet is 
consistent in both gas pathway designs, so the modification has no effect on resulting gas 
exchange. 
 
 
 
   
Figure 2.2. IPRAC indwelling impellers, blood/gas pathways, and vascular placement. (A) Tear-
away view of IPRAC fiber bundle showing indwelling safety coil and impellers on driveshaft. 
(B) An enlarged view of sweep gas versus blood pathways in a single HFM. Pure O2 gas flows 
into the fiber lumen and an O2 + CO2 gas mixture exits at fiber outlet. Blood flows on the outside 
of the fiber, separated from sweep gas flow by the microporous fiber wall. (C) IPRAC insertion 
to the inferior vena cava (IVC) via the femoral vein with percutaneous gas pathway and driveline 
tubing.  
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Following initial testing, the impellers with greatest CO2 removal rates in the modified 
IPRAC were incorporated into full IPRAC prototypes for gas exchange evaluation.  
2.2.2 Impellers 
All impellers were designed in SolidWorks (Concord, MA) and fabricated at the University of 
Pittsburgh Swanson Center for Product Innovation (Pittsburgh, PA) from a hydrophobic epoxy 
resin (Watershed XC11122; DSM Somos, Sittard, Netherlands) using stereolithography (SLA). 
Impellers measured 10 mm in length with a maximum outer diameter of 4 mm. The reduction in 
driveshaft diameter from 0.090” (2.3 mm) in previous work to 0.042” (1.07 mm) allowed design 
of taller blades with increased surface area. The six impeller blade designs evaluated are shown 
in Figure 2.3. The Flat Blade design is similar to the top performing geometry from previous 
work but has 3-fold increased blade surface area to enhance potential fluid volume displacement. 
Each of the Curved, Flat-Tangent, and Radial-Tangent blades (where the Radial-Tangent design 
is a combination of the Curved and Flat-Tangent blades) were designed with the objective of 
minimizing the change in velocity vector directionality of incident flow. The Crescent blade was 
designed to funnel flow toward the center of the impeller, with the objective of focusing 
generated flow to a single region on each blade. All impellers had 2-5 blades. Impellers were 
glued to the distal 280 mm of flexible drive shafts. Axial separation distance between impellers 
was set at 2 or 10 mm, resulting in a total of 23 or 14 impellers, respectively.  
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Figure 2.3. IPRAC impeller designs. Six impeller geometries evaluated in in vitro gas exchange 
studies. Each impeller measures 10 mm in length with maximum outer diameter of 4 mm. 
 
 
 
 The design of blades and determination of the optimal combination of blade design, axial 
spacing, and number of blades was a progressive process. The Flat, Flat-Tangent, Curved, and 
Flat-Tapered impellers were designed and tested first with 4 blades and 10 mm axial separation. 
As design characteristics and arrangements were shown experimentally and in CFD simulations 
to be beneficial, or not, for gas exchange (e.g. axial separation, 45° taper on blade ends, etc.), 
these features were selectively implemented into later designs (i.e. Radial-Tangent and Crescent 
blades). As a result, not all designs were tested with varying number of blades or at multiple 
axial separation distances. The combinations of blade number and impeller spacing for the 
geometries tested are listed in Table 2.1. 
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Table 2.1. Design matrix of IPRAC blade parameter combinations evaluated in vitro. 
Blade Design 
With 10-mm spacing 
(14 impellers) 
With 2-mm spacing 
(23 impellers) 
Flat 4 blades only 4 blades only 
Flat-Tapered 4 blades only 3, 4, or 5 blades 
Flat-Tangent 4 blades only — 
Curved 4 blades only — 
Radial-Tangent — 2, 3, or 4 blades 
Crescent — 3 or 4 blades 
 
2.2.3 In Vitro Flow Loop and Gas Exchange Testing 
Gas exchange testing was performed in an in vitro recirculation loop (Figure 2.4), as described 
by Eash et al. [58]. The loop consisted of a reservoir, centrifugal pump (BPX-80; Medtronic, 
Minneapolis, MN), two commercial oxygenators (Vision Hollow Fiber Oxygenator; Gish 
Biomedical, Rancho Santa Margarita, CA) to control inlet CO2 gas tension, and the modified 
IPRAC device within a 7/8-in ID acrylic test section. Pure O2 sweep gas was pulled through the 
fiber bundle at 3.0 L/min by a sealed vacuum pump (N811 KV.45P; KNF Neuberger Inc., 
Trenton, New Jersey) and regulated with a thermal mass flow controller (GR-116-1-A-PV-O2; 
Fathom Technologies, Georgetown, Texas). Pressure drop across the fiber bundle was monitored 
with differential transducers (143C; Honeywell International, Inc., Morristown, NJ). We have 
shown previously that measured CO2 removal in water bench testing correlates well with in vivo 
performance (within ≈10%) for IPRAC devices, so for simplicity all testing was performed in 
deionized water at 37°C [5, 101]. Water flow rate was maintained at 3.0 L/min in the loop and 
monitored with a clamp-on ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY). Water 
pressure at the test section inlet was measured with a liquid pressure transducer (PX771-025DI; 
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Omega Engineering Inc., Stamford, CT) and maintained at physiologically relevant venous 
pressures (10-15 mmHg).  
 
 
 
 
Figure 2.4. IPRAC in vitro gas exchange loop. 
 
 
 
The CO2 and O2 gas tensions in the fluid were measured with a blood gas analyzer 
(RapidLab 248; Siemens, Erlangen, Germany). Inlet pCO2 was adjusted to conditions relevant to 
venous blood (pCO2 = 50 ± 5 mmHg) via a CO2/N2 gas mixture through commercial 
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oxygenators. The outlet sweep gas CO2 concentration was measured with a gaseous CO2 
analyzer (WMA-4; PP Systems, Amesbury, MA). Inlet O2 partial pressure was not regulated but 
was typically steady around 25 ± 10 mmHg.  
Gas exchange was evaluated for each impeller rotating at 20,000 RPM. The fraction of 
CO2 in the outlet gas was used to calculate total CO2 removal, 𝑉𝐶𝑂2, according to Equation 2.1, 
as the product of the fraction of CO2 exiting the fibers, 𝐹𝐶𝑂2, and the STP corrected mass flow 
rate of the sweep gas, 𝑄𝑂𝑈𝑇
𝑆𝑇𝑃 .  
 𝑉𝐶𝑂2 = 𝑄𝑂𝑈𝑇
𝑆𝑇𝑃 𝐹𝐶𝑂2 2.1 
To reduce variability associated with small differences (< 5 mmHg) between trials, 𝑽𝑪𝑶𝟐 
was then normalized (𝑽𝑪𝑶𝟐
∗ ) to our target inlet pCO2 of 50 mmHg according to Equation 2.2.  
 
𝑉𝐶𝑂2
∗ = 𝑉𝐶𝑂2 ∙
50 𝑚𝑚𝐻𝑔
𝑝𝐶𝑂2
𝐼𝑁𝐿𝐸𝑇  2.2 
2.2.4 Statistical Analysis 
Reported gas exchange values are the average of 6-8 measurements each. Significance testing 
was performed in SPSS (PASW Statistics 18; IBM, Armonk, NY). Student’s or paired t-tests and 
ANOVA were conducted with subsequent posthoc testing when all assumptions for parametric 
testing were satisfied. Assumptions required for parametric analysis include: 1) homogeneity of 
variance (i.e. homoscedasticity) as determined by Levene’s test, 2) normally distributed data 
(Kolmogorov-Smirnov test), and 3) equal group sample sizes. With violation of the first 
assumption, or if both the second and third assumption were violated, the non-parametric 
Kruskal-Wallis test was used in place of ANOVA. Non-parametric posthoc comparisons of 
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means were conducted with the Mann-Whitney U test coupled with a Bonferroni correction to 
avoid inflation of a Type I (false positive) error rate.   
2.3 RESULTS 
2.3.1 Spacing Effects 
The Flat and Flat-Tapered blades were each tested side-by-side with 2 mm and 10 mm axial 
separation to investigate spacing effects on gas exchange efficiency. A small (5-10%) 
improvement in CO2 removal rate (p<0.005) was achieved at 2 mm separation for both 
geometries tested (Figure 2.5A). Normalizing the gas exchange rate to the number of impellers 
(Figure 2.5B) showed that reducing the separation gap resulted in a 35% (Flat blade) and 28% 
(Flat-Tapered blade) decrease in gas exchange per impeller.  
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Figure 2.5. Impeller Spacing effects on IPRAC gas exchange. All impellers were fixed to a 270 
mm section of driveshaft at either 2 mm or 10 mm axial spacing between impellers. At the 
shorter (2 mm) and longer (10 mm) axial separation distances 14 and 23 impellers were attached 
in total, respectively. Plots show CO2 removal rates of Flat and Flat-Tapered impellers (with 4 
blades) at both 2 and 10 mm axial spacing with normalization for (A) fiber surface area, 𝑽𝑪𝑶𝟐
∗ /𝑨, 
mL/min/m2 or (B) fiber surface area and number of impellers, 𝑽𝑪𝑶𝟐
∗ /𝑨/𝑰𝒎𝒑𝒆𝒍𝒍𝒆𝒓𝒔, 
mL/min/m2/Impellers. 
 
 
 
2.3.2 Comparison of Impeller Blade Designs 
Six unique impeller designs were compared with either 10 mm (Figure 2.6A) or 2 mm (Figure 
2.6B) axial separation with four blades each. Due to the progressive nature of the testing process, 
not all designs were evaluated at both 10 and 2 mm separation. The Curved and Flat-Tangent 
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blades were not shown to significantly affect gas exchange versus the Flat blade at 10 mm 
separation, so were not tested later at 2 mm separation after it was determined the shorter axial 
spacing was beneficial. The Radial-Tangent and Crescent blades that were designed last were 
only tested at the more advantageous 2 mm separation distance. The Curved and Flat-Tangent 
blades outperformed the Flat-Tapered blade in gas exchange testing by a small (5-8%) but 
statistically significant (p<0.005) margin. No other designs were found to differ statistically with 
10 mm separation, however comparison of Flat to the Flat-Tapered failed to meet the required p-
value by a small margin (p=0.009, but required p-value from Mann-Whitney non-parametric 
comparison of means with Bonferroni correction was p<0.0083). Statistical comparison of means 
found the measured CO2 removal data for the Flat, Flat-Tapered, Radial-Tangent, and Crescent 
blades (2 mm axial spacing) to differ insignificantly (p=0.072), suggesting no statistical 
difference exists between these designs. 
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Figure 2.6. Effect of IPRAC blade design on gas exchange. CO2 removal rate normalized to 
fiber surface area (0.07 m2) of six impeller designs, each with 4 blades. (A) Data shown for 
impellers with 10 mm axial separation. (B) Data shown for impellers with 2 mm axial separation. 
 
 
 
The 45° chamfer (taper) that distinguishes the Flat and Flat-Tapered designs was not 
shown to affect gas exchange experimentally at either 2 mm or 10 mm separation. Since no 
disadvantage in gas exchange was demonstrated for the tapered blade modification, this feature 
was incorporated into blades designed after that finding (i.e. Crescent and Radial-Tangent).  
2.3.3 Number of Blades 
Three designs (Flat-Tapered, Radial-Tangent, and Crescent) were each tested with varying 
number of blades (Figure 2.7). The achievable gas exchange rates with the Flat-Tapered and 
Crescent impellers were both found to be independent of the number of blades in head-to-head 
comparisons (p=0.24 and p=0.97, respectively). Only the Radial-Tangent impellers achieved 
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statistically differing gas exchange rates (p=0.01). CO2 removal rates of the Radial-Tangent 
design with two blades were 5% (p=0.006) and 4% (p=0.015) less than the same design with 
three-blade and four-blades, respectively. While gas exchange rates were shown to differ 
statistically for one design with varying numbers of blades (Radial-Tangent), the overall effect 
for all devices tested was marginal (~0-5%). 
 
 
 
 
Figure 2.7. Effects of blade frequency on IPRAC gas exchange. CO2 removal rate normalized to 
fiber surface area (0.07 m2) versus blade number on impellers with (A) Crescent blades, (B) 
Radial-Tangent blades, and (C) Flat-Tapered blades. Each impeller device had 2 mm axial 
separation. †p<0.001, **p<0.05. 
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2.3.4 Full IPRAC Prototype Gas Exchange Testing 
Following in vitro gas exchange testing with the modified catheter device, full IPRAC prototypes 
were manufactured that incorporated impellers with either the Crescent, Flat-Tapered, or Radial-
Tangent blades. Each device consisted of impellers with three blades and 2 mm axial spacing. 
The gas exchange performances of the full IPRAC devices are shown in Figure 2.8. The highest 
CO2 removal rate (573 ± 8 mL CO2/min/m
2) was achieved with the Crescent blade, followed by 
the Flat-Tapered (535 ± 17 mL CO2/min/m
2) and the Radial-Tangent (516 ± 7 mL CO2/min/m
2) 
prototypes. With the exception of the Crescent blade that achieved 11% greater CO2 removal in a 
full IPRAC device versus the modified catheter, the gas exchange data generally agreed between 
full and modified IPRAC devices. In full prototypes the Flat-Tapered and Radial-Tangent blades 
performed 6% and 3% greater than in testing with the modified device. 
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Figure 2.8. CO2 removal rates of full IPRAC prototypes. Prototypes contained either Crescent, 
Flat-Tapered, or Radial-Tangent blade designs. Each impeller contained 3 blades and was 
separated axially by 2 mm. 
 
 
2.4 DISCUSSION 
In vitro testing demonstrated that CO2 removal achieved with impeller rotation was improved by 
reducing axial spacing and increasing the total number of rotating impellers. The design of the 
blade as well as the number on each impeller was not found to significantly influence gas 
exchange. Our top performing impeller arrangement achieved a CO2 removal rate of 573 ± 8 
mL/min/m2 (40.1 mL/min) in a full IPRAC device, an improvement of ~10% versus previous 
work [5].  
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The mechanisms by which an actively mixed system can facilitate HFM mediated gas 
exchange in blood oxygenators has been described previously [51, 101–103]. In short, impeller 
rotation adds orthogonal velocity components to bulk movement in the vessel, resulting in cross-
flow through the fiber bundle and increased fluid velocity at the membrane surface. Greater 
velocity and bundle cross-flow diminish the highly limiting diffusive boundary layer at the gas 
exchange surface, facilitating maintenance of stronger gaseous concentration gradients spanning 
fiber walls [51]. The significance of this enhancement is emphasized when considering the effect 
of impeller facilitated active mixing on the mass exchange effectiveness parameter. The ratio 
(~0-1) of achieved CO2 removal versus maximum possible removal normalized for blood flow 
rate, gas flow rate, and 𝑝𝐶𝑂2
𝐼𝑁𝐿𝐸𝑇, increases >15-fold from 0.012 to 0.203 with impeller rotation 
at 20,000 RPM versus passive gas exchange (i.e. 0 RPM) [104].  
Among potential factors contributing to gas exchange, our results suggest that indirect 
and direct interactions between neighboring impellers are of importance. When axial separation 
distance is reduced from 10 mm to 2 mm, the length of the fiber bundle associated with each 
impeller (i.e. bundle length/# impellers) decreases by 40%. We believe the CO2 removal 
efficiency of each impeller (i.e. 𝑉𝐶𝑂2
∗ /𝐴/𝐼𝑚𝑝𝑒𝑙𝑙𝑒𝑟𝑠) with 2 mm axial spacing is affected by the 
reduced bundle surface area associated with each impeller. Figure 2.9 shows CFD predicted 
velocity profiles in fluid surrounding impellers and the flow pathways of fluid as affected by 
rotating impellers. Above each rotor, fluid is strongly propelled radially outward through the 
fiber bundle before recirculating inward back through the bundle in the space between impellers. 
As the distance between impellers shrinks, the resistance to inward flow increases, reducing the 
pumping efficiency of each impeller and the associated contribution to gas exchange. In 
simulations we demonstrated that a 45° chamfer (taper) at the blade ends mitigated this 
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interference and diminished the losses in efficiency for individual impellers at 2 mm versus 10 
mm spacing (22% predicted improvement in CO2 removal at 2 versus 10 mm for Flat-Tapered, 
16% for Flat). Predicted gas exchange performance versus each experimental dataset are shown 
in Figure 2.10. Experimentally the 45° chamfer did not significantly affect overall gas exchange 
(i.e. the Flat and Flat-Tapered did not differ statistically at 2 mm spacing or at 10 mm spacing) 
but the improvement in total CO2 removal at 2 versus 10 mm spacing for the Flat-Tapered blade 
(18%) exceeded that of the Flat blade (7%). The effects of the blade taper are logically not 
inclusive of gas exchange, and could possibly contribute a hemocompatibility advantage as well 
given that attenuating flow interference may lessen stresses exerted on blood cells. Given that 
our overall gas exchange improved with 23 versus 14 impellers despite the 28-34% reduced 
contribution of individual impellers, we proceeded with testing of new blade designs (Crescent 
and Radial-Tangent) exclusively at 2 mm spacing. Considering the potential benefits to gas 
exchange and hemocompatibility each was designed with a 45° taper at the end of each blade.  
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Figure 2.9. CFD predicted fluid velocities in the IPRAC with impeller mixing. 3 L/min of bulk 
flow from left to right. Light and dark contour regions correspond to fluid velocity (in m/s) in 
positive radial direction (away from shaft) and negative radial direction (toward the shaft), 
respectively. (A) Flat blade 2 mm spacing (B) Flat-Tapered blade at 2 mm axial spacing. 
 
 
 
Each impeller chosen for testing in full IPRAC prototypes was fabricated with three 
blades. The failure to show any significant effect of blade number on gas exchange for the 
designs tested suggests that only a few impeller blades provide the necessary orthogonal velocity 
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components required to create efficacious active mixing conditions. We also theorized that 
additional blades would exert additional shear stresses and viscous energy dissipation to the 
fluid. Given the conceivable advantage to hemocompatibility and equivalent contribution to gas 
exchange, we concluded that incorporating more than three blades was inessential. The 
discrepancy in performance between the modified and full IPRAC devices containing the same 
impellers/arrangements may be due in part to the manufacturing process, given that the fiber 
bundle is wrapped and potted for each device by hand.   
 
 
 
 
Figure 2.10. CFD predicted versus experimental gas exchange rates in the IPRAC. CO2 removal 
rates normalized to fiber surface area (0.07 m2). Group nomenclature: Impeller Name (Number 
of blades, Impeller separation distance in mm). 
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The CFD simulation model developed for the IPRAC in collaboration with Dr. Burgreen 
was valuable for flow visualization and drove our progressive design process. Formal 
optimizations of impeller blade designs were not conducted however. A limitation of developing 
a CFD model for a complex flow system such as the IPRAC is that not all nuances of device 
operation can be captured with exact fidelity. For example, the use of a non-rigid driveshaft that 
provides the IPRAC with the necessary flexibility for insertion and operation in tortuous 
environments does not prevent radial impeller movement within the safety coil. It is possible that 
operational subtleties such as this affect resulting gas exchange non-negligibly, but would be far 
too complex to accurately predict in a CFD model. Despite this, the error associated with our gas 
exchange model was reasonably acceptable (2-13%), and accurately predicted the overall 
benefits of reducing impeller axial spacing, which we demonstrated to be the most influential 
parameter investigated. This finding suggests that our model may be beneficial for identifying 
design features and impeller arrangements that profoundly influence gas exchange in future 
studies. 
Rotation speed remains an important factor in active mixing, as was shown for all 
geometries tested previously [5]. Other possible design parameters or arrangements that may 
contribute to gas exchange that were not investigated in this work are impeller length or 
driveshaft orientation relative to other impellers (i.e. aligned with blades offset to neighboring 
impeller). Collectively though these results suggest that at constant impeller rotation rates, we 
may expect little further improvement in gas exchange with optimization of impeller blade 
designs and arrangements.  
The resulting CO2 removal rate of the IPRAC after investigation of impeller 
arrangements and design is ~2/3 of the target rate of ≥65 mL/min. We hypothesized that 
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improvements to the impeller design would enable reduction of the insertion diameter from the 
current 25 Fr to a more clinically relevant diameter <20 Fr. Due to the modest improvement in 
total gas exchange performance it is not feasible with the current IPRAC design to reduce the 
device diameter. Decreasing the IPRAC insertion size would require a combination of reducing 
the HFM surface area and reducing impeller blade size, both of which are expected to negatively 
impact gas exchange performance. A potential method of improving gas exchange would be 
incorporation of carbonic anhydrase (CA) immobilized fibers. This approach was shown to 
enhance CO2 removal by 37% in blood [7].  The combination of CA-fibers and active mixing 
may have an additive or synergistic effect on CO2 removal. Recent studies, however, suggest the 
CA fibers may be most effective at blood flow rates significantly lower than those relevant to the 
IPRAC (<500 mL/min) [84]. This topic is further discussed in Chapter 6.0. 
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3.0 IPRAC IN VITRO HEMOLYSIS TESTING 
3.1 INTRODUCTION 
Blood cell hemolysis refers to the rupture of erythrocytes in blood and dispensing of cellular 
contents into the plasma. This is a naturally occurring process as red blood cells age and lyse, 
however in the presence of blood contacting devices this process can be expedited due to 
mechanical trauma. Plasma free hemoglobin (pfHb) is generally eliminated from the plasma by 
conjugating with α-2-globulin to form a haptoglobin complex before reticuloendothelial 
clearance, however this pathway is exhausted at plasma hemoglobin concentrations exceeding 
~130-150 mg/dL [105, 106]. High concentrations of hemoglobin in the plasma can result in 
deposition into body tissues, hemoglobinuria, and can eventually lead to endothelia cytotoxicity 
and excessive nitric oxide scavenging [107–109].  
Hemocompatibility studies are of special interest for the impeller percutaneous 
respiratory assist catheter (IPRAC) since hemolysis is often associated with shear due to rotating 
parts, narrow clearances, and mechanical components necessary in these systems (e.g. bearings, 
seals) in blood pumps [110–113]. A systematic approach to determine the relationship between 
in vitro hemolysis and active mixing was undertaken to identify components of the impeller 
system that may contribute to hemolysis.   
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The objectives of the hemolysis studies reported in this chapter were to establish if 
specific aspects of the IPRAC design contributed to erythrocyte trauma. Hemolysis tests focused 
on five aspects of the IPRAC design that we suspected may contribute to cell damage based on 
reports from the blood pump literature [110–114]. (1) Impeller rotation, (2) contact between 
impellers and the surrounding safety coil, (3) surface roughness of impellers, (4) flow through 
the fiber bundle, and (5) contact between the rotating shaft and static components were each 
investigated independently. Modified IPRAC prototypes were designed and fabricated to 
evaluate each potential source of cell damage. Hemolysis associated with each design component 
was estimated by comparison of a modified IPRAC device versus the same device with that 
specific component removed. Impellers were found to contribute to minimal hemolysis in the 
absence of the surrounding safety cage. Contact between the impellers and the surrounding cage 
was found to account for the majority of cell damage observed in the IPRAC. When impeller 
surfaces were polished however, hemolysis associated with impeller/cage contact was largely 
eliminated, indicating surface roughness played a major role in contact-trauma between the 
impellers/cage. All other sources of cell damage investigated were found to contribute to 
minimal hemolysis. 
3.2 METHODS 
3.2.1 In Vitro Hemolysis Testing 
The hemolysis test loop (Figure 3.1) consists of a basic recirculation loop similar to that 
described in Section 2.2.3 (page 28), depicted in Figure 2.4. Components relevant specifically to 
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gas exchange were removed, including the commercial oxygenator and the IPRAC gas pathway 
equipment. The large blood reservoir in the gas exchange circuit was replaced with a 1 L blood 
reservoir bag, which was submerged in a heated water bath to regulate the temperature of 
recirculating blood at 37 ± 1°C. Filtered and anticoagulated (20 U/mL) bovine blood was 
collected fresh from the slaughterhouse the morning of testing. Blood was conditioned with 
gentamicin (100 u/L) and hemoglobin corrected to 12 g/dL according to ASTM standards 
(F1841-97) [115]. Blood was recirculated at test conditions for 1 hour prior to sample collection 
to lyse older and fragile red cells that may spike early hemolysis measurements. Each test was 
run for 3 hours following initial recirculation, with samples drawn every 30 minutes. Impeller 
speed was maintained at 20,000 RPM in all tests and blood flow rate was set to 3.0 L/min with a 
blood pump (BPX-80; Medtronic, Minneapolis, MI, USA). Fluid pressure was monitored in the 
test section using a differential liquid pressure transducer (PX771-025DI; Omega Engineering, 
Inc., Stamford, CT, USA) and adjusted to venous pressures (10-15 mmHg) using a Hoffman 
clamp. 0.9% saline was continuously infused along the shaft (15 mL/hr) to lubricate and protect 
the seal and bearing from blood backflow up the driveshaft. 
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Figure 3.1. Recirculation loop for in vitro hemolysis testing with the IPRAC. 
 
 
 
Plasma free hemoglobin (pfHb) was measured by centrifuging whole blood in two steps 
(15 minutes at 800 g, 10 minutes at 7,200 g) and analyzing supernatant plasma 
spectrophotometrically (Genesys 10S UV-Vis; Thermo Scientific, Waltham, MA, USA) at 
540 nm. PfHb concentration was calculated from absorbance using a standard curve developed 
from a linear-fit of serially diluted whole blood with 100% hemolysis versus absorbance [116]. 
A Normalized Index of Hemolysis (NIH) that reports the rate of increasing pfHb in grams per 
100 liters of blood flow through the device was calculated according to Equation 3.1. 
 
𝑁𝐼𝐻 = Δ𝑝𝑓𝐻𝑏 × 𝑉 ×
100 − 𝐻𝐶𝑇
100
×
100
𝛥𝑡 × 𝑄
 3.1 
where 𝑁𝐼𝐻 = normalized index of hemolysis (g/100L), Δ𝑝𝑓𝐻𝑏 = increase in pfHb over the 
sampling time interval (g/L), 𝑉 = total circuit blood volume (L), 𝐻𝐶𝑇 = hematocrit (%), Δ𝑡 = 
sampling time interval (min), and 𝑄 = average blood flow rate (L/min). 
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3.2.2 Test Devices 
3.2.2.1 Full IPRAC 
A baseline measurement for IPRAC generated hemolysis was determined with a full prototype 
previously used in gas exchange studies (“IPRAC” in results). The IPRAC prototype (23 
Crescent impellers, 3 blades, 2 mm spacing – see Section 2.2.1) was inserted to the loop and 
suspended in the center of the test section with intersecting set screws, shown in Figure 3.2. A 
matching control loop with an empty test section was run in parallel to estimate the rate of cell 
damage due to circuit components independent of the IPRAC (e.g. blood pump, etc.). The 
control loop hemolysis measurement was subtracted from the IPRAC NIH value to determine the 
rate of cell damage for the test device. A summary of all tested devices is provided at the end of 
this section inTable 3.1, with specific comparisons summarized in Table 3.2. 
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Figure 3.2. Distal manifold supporting rigid IPRAC shaft during hemolysis testing. Intersecting 
set screws suspend the IPRAC in the center of the test section. The rigid shaft terminates in the 
manifold tubing (PTFE), which is continuously flushed with saline.  
 
 
 
3.2.2.2 Mag-Lev Device 
Hemolysis due to impeller rotation was evaluated in a modified device with surrounding fiber 
bundle and safety coil removed (“Mag-Lev” device). Impellers were fit to a rigid stainless steel 
shaft (diameter matching flexible shaft diameter, 0.042”) with intermittent annular magnets to 
maintain shaft stability in the absence of the surrounding safety coil. The arrangement of 
permanent magnets on the shaft is shown in Figure 3.3 (left). with the final arrangement of 
supportive magnets on the housing shown in Figure 3.3 (right). The final arrangement of 
magnets on the housing consisted of three fixtures holding 20-30 cylinder magnets on the 
housing (Figure 3.3, right) in addition to proximal and distal shaft support (Figure 3.2).  
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Figure 3.3. “Mag-Lev” IPRAC with magnetically levitated driveshaft for hemolysis testing. 
(left) Driveshaft shown with mounted magnets adjacent to impellers fixed on shaft. (right) Final 
arrangement of magnets on housing necessary for stable rotation at 20,000 RPM consisted of 
magnet arrays on three fixtures in addition to proximal and distal shaft support. 
 
 
 
 
The specific contribution of impeller rotation to hemolysis was estimated by subtracting 
NIH of a control device with no impellers (“Blank Driveshaft” described below) from the Mag-
Lev NIH value. A similar approach was taken to systematically estimate the NIH values 
associated with each design component of interest. The specific design aspects evaluated and the 
comparisons used for estimation are summarized in Table 3.2.  
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3.2.2.3 Blank Driveshaft Device 
The third test device consisted of a rigid shaft with no impellers (“Blank Driveshaft” device). 
The shaft was supported by proximal and distal manifolds as shown in Figure 3.2. Measured 
NIH values were compared to the Mag-Lev device to estimate the contribution of impeller 
rotation to IPRAC hemolysis. This device was also used to evaluate if rotation of the driveshaft 
against static components caused cell damage by comparison it to the empty loop control circuit. 
A saline infusion (15 mL/hr) was connected to both proximal and distal manifolds to prevent 
blood backflow up shaft tubing. The full IPRAC prototype has only the proximal manifold to 
support the flexible driveshaft, which is accounted for when considering the contribution of these 
components by halving the calculated NIH value after subtracting the empty loop NIH. 
3.2.2.4 Fiberless IPRAC – Stock Impellers 
The fourth device tested was most similar in design to the full IPRAC prototypes, but had the 
fiber bundle removed (“Fiberless (stock impellers)” device). Impellers were fixed to a flexible 
driveshaft and rotated inside a safety coil as shown in Figure 3.4. This device allowed the 
contribution of the fiber bundle to be evaluated through comparison of hemolysis to the full 
IPRAC. The contribution of impeller/cage contact to hemolysis could also be investigated 
through comparison to the Mag-Lev device, allowing hemolysis associated with the impellers 
and manifolds to be controlled for.  
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Figure 3.4. IPRAC impellers in safety coil used for hemolysis testing. “Fiberless (stock 
impellers)” device shown with crescent impellers (three blades, 2 mm shaft spacing). 
 
 
 
3.2.2.5 Fiberless IPRAC – Polished Impellers 
The final modified IPRAC device was built to investigate the effects of impeller surface 
roughness on hemolysis (“Fiberless (polished impellers)” device). Physical stress on red cells 
caught between impellers and the cage may be exacerbated with roughened surfaces. To 
investigate the effects of surface roughness during impeller/cage contact, stock impellers were 
re-coated with fresh resin (Watershed XC11122; DSM Somos, Sittard, Netherlands) hardened 
under UV. Impellers were incorporated into the Fiberless IPRAC prototype described above for 
direct comparison to that device. Surface roughness of impellers were qualitatively compared 
using scanning electron microscopy (SEM). Stock impellers, polished impellers, and stock 
impellers with wear (used in >5 experiments) were imaged. The Fiberless (polished impellers) 
device performance was compared to the Mag-Lev device to estimate hemolysis associated with 
polished impeller contact with the surrounding cage.  
 53 
Table 3.1. Summary of modified IPRAC prototypes used for in vitro hemolysis testing. 
Test Device Device Description: 
1) IPRAC Full IPRAC prototype (Figure 2.1A). Stock impellers. 
2) Fiberless (stock impellers) 
IPRAC with fiber bundle removed (Figure 3.4). Stock 
impellers. 
3) Fiberless (polished impellers) 
IPRAC with fiber bundle removed (Figure 3.4). Polished 
impellers. 
4) Magnetically Levitated Shaft 
IPRAC with fiber bundle and safety coil removed. 
Impellers supported by magnet array on shaft and 
housing (Figure 3.3). Stock impellers. 
5) Blank Driveshaft 
IPRAC with fiber bundle, safety coil, and impellers 
removed.  
6) Empty Loop (control) Empty test section 
 
 
 
3.3 RESULTS AND DISCUSSION 
Plasma free hemoglobin (pfHb) concentrations measured during testing of the full IPRAC 
prototype over 3 hours are shown in Figure 3.5 alongside the control (empty) loop that was 
tested in parallel. PfHb concentrations rise linearly, which is representative of the consistency 
between measurements over the testing period for all datasets reported in this chapter (not all 
data shown).  
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Figure 3.5. IPRAC in vitro hemolysis as total pfHb (g) versus Δt (min). Rate of accumulating 
pfHb in the recirculating loop was linear (R2 > 0.95) over the testing period in all devices, 
including those not shown. 
 
 
 
 
Figure 3.6. In Summary of in NIH values measured during IPRAC in vitro hemolysis studies. 
Device descriptions are summarized in Table 3.2. 
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The calculated NIH value for the full IPRAC prototype was 0.228 g/100L versus 0.007 
g/100 L in the empty control loop. The estimated baseline NIH value for the IPRAC is therefore 
0.221 g/100L after controlling for the empty loop performance. A NIH value ≤0.05 g/100L is 
generally considered an acceptable rate of cell damage in the blood pump literature [117]. This 
value is often reported for artificial lung devices as well, despite the absence of recent studies 
validating that exceeding this benchmark value translates to unacceptable in vivo performance. 
The estimated NIH for the IPRAC is significantly greater than the acceptable NIH value, 
indicating the existing design would likely cause unmanageable levels of cell damage in vivo. 
Following this result a series of hemolysis studies were conducted with the IPRAC. The 
objective of hemolysis studies were to identify design elements of the impeller system that 
contribute to cell damage so they can be addressed/eliminated from future IPRAC designs, or in 
other devices utilizing rotating impellers. The average NIH values of notable device 
configurations are summarized in Table 3.1 and discussed further below. 
An IPRAC prototype was fabricated with a magnetically levitated driveshaft (“Mag-
Lev”) (Figure 3.3) to determine if impeller rotation at speeds necessary for effective active 
mixing is inherently hemolytic. The measured NIH of the Mag-Lev device over three 
experiments (n=3) was within the acceptable range at 0.029 ± 0.002 g/100L. Proximal and distal 
supports (Figure 3.2) were required in the Mag-Lev setup however, which may have contributed 
to some of the observed hemolysis in these studies. To control for hemolysis associated with the 
manifolds the Mag-Lev NIH was normalized by the Blank Driveshaft (i.e. no impellers) device 
with proximal and distal supports. The observed rate of hemolysis in the Blank Driveshaft 
experiments (n=4) was 0.023 ± 0.006 g/100L. Controlling the Mag-Lev hemolysis for the Blank 
Driveshaft device, the estimated NIH value associated with impeller rotation is 0.007 ± 0.002 
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g/100L. Similar normalizations were made between each of the modified IPRAC prototypes to 
isolate contributions associated with specific design components. Estimated hemolytic 
contribution of each IPRAC design component is summarized in Figure 3.7, with groups used for 
comparisons listed in Table 3.2. Not directly investigated here were non-contact shear effects 
associated with rough surfaces moving at high velocities that can contribute to hemolysis [114, 
118, 119].  The Mag-Lev device performance suggests surface roughness plays an insignificant 
role in the current impeller system, however, based on the estimated NIH for that device using 
unpolished (stock) impellers. Testing indicates that impeller generated cell damage in the IPRAC 
is minimal in the absence of safety coil contact, and suggests that the impeller system may be 
adopted safely in new devices that could benefit from active mixing (e.g. extracorporeal CO2 
removal devices) or future IPRAC prototypes if other sources of hemolysis can be resolved.  
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Figure 3.7. Estimated contribution to hemolysis of each IPRAC design component. Each dataset 
represents the estimated NIH value contributed by a single aspect of the IPRAC. Values were 
determined by normalizing test devices by data available for all other components. Test devices 
and controls for each design component listed are summarized in Table 3.2. 
 
 
 
To identify other sources of hemolysis in the IPRAC, the fiber bundle and impeller/cage 
interactions were investigated. Material effects or high shear flow through the fiber bundle are 
possible mechanisms of hemolysis, and each can be evaluated for cell damage by comparison of 
the full IPRAC prototype to a comparable device with the fiber bundle removed (Figure 3.4). 
Contact between impellers and the surrounding safety coil may also contribute to significant 
levels of cell damage. Friction between rotating impellers and the static coil generates an 
unknown amount of heat, which at significant levels is known to cause hemolysis and clotting 
[110]. Blood cells caught between the impeller surface and the coil may also be physically 
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ruptured. Each of these mechanisms of hemolysis can also be evaluated with a fiber-less 
prototype (Fiberless (stock impellers) device) by comparison to the magnetically levitated 
device, which differs only in the presence of the safety coil. The device described above (Figure 
3.4) was tested (n=7) and found to have a measured NIH = 0.191 ± 0.019 g/100L. Controlling for 
hemolysis contributed by impeller rotation and the proximal manifold, the normalized NIH 
associated with impeller/cage contact is ~0.162 ± 0.019 g/100L. This accounts for the vast 
majority of the blood damage observed in the full IPRAC prototype, and suggests impeller/cage 
interacts are the primary cause of hemolysis. Bundle effects account for the remaining hemolysis 
in the system, ~0.037 g/100L (full IPRAC prototype NIH, normalizing for impeller/cage contact, 
impeller effects, and manifolds). 
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Table 3.2. Summary of IPRAC design components investigated for in vitro hemolysis. Test 
Devices and Control devices differ only by the Design Component being investigated. E.g. Fiber 
Bundle effects were quantified by removing the fiber bundle from the full IPRAC device. 
Design Component Evaluated  Test Device: Controlled for: 
1) Fiber Bundle Full IPRAC 
Fiberless 
(stock impellers) 
2) Impeller/Cage Interactions 
     (stock impellers) 
Fiberless 
(stock impellers) 
Mag-Lev Shaft 
3) Impeller/Cage Interactions 
     (polished impellers) 
Fiberless 
(polished impellers) 
Mag-Lev Shaft 
4) Impeller Rotation Mag-Lev Shaft Blank Driveshaft 
5) Manifolds/Rotating Shaft Blank Driveshaft Control Loop 
 
 
 
 
Cell damage related to impeller/cage interactions could manifest in various ways. Heat 
generated from friction or physical trauma from cells being trapped between impellers and the 
coil at the time of contact could each cause hemolysis. Surface finish of impellers may play an 
important role in the severity of cell damage through impeller/cage interactions, and was 
investigated further by incorporating polished impellers into a fiber-less IPRAC device with a 
surrounding coil (Figure 3.4). Hemolysis generated by the test device had a NIH = 0.036 g/100L, 
which when normalized for cell damage associated with impeller rotation and manifold 
(magnetically levitated result) is ~0.007 g/100L. Surface finishes of impellers were qualitatively 
compared with SEM (Figure 3.8) imaging, revealing improvements in surface finish after 
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polishing impellers. The improvement in hemolysis testing with polished impellers suggests that 
the primary contributor to hemolysis in the IPRAC is impeller/cage interactions, but this may be 
alleviated with modifications to the impeller.  
 
 
 
    
Figure 3.8. SEM images of IPRAC impeller blades detailing surface finish. (left) Blade of stock 
impeller at 150X detailing roughness on surface. (right) Smooth blade of polished impeller at 
150X. 
 
 
 
Hemolysis studies in modified IPRAC devices were conducted to determine if cell 
damage was a concern in the existing prototype. The contribution to hemolysis associated with 
the impellers, manifolds, impeller/cage interactions, surface effects (roughness), and the fiber 
bundle were each estimated through systematic comparisons in modified IPRAC prototypes. 
Impeller rotation was found to be minimally traumatic to blood cells, indicating they can be 
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safely used in future IPRAC devices or new extracorporeal CO2 removal devices. Other 
components of the IPRAC design such as the manifolds where the shaft enters the blood 
compartment and the fiber bundle were also found to contribute to low levels of hemolysis. 
Impeller/cage interactions were identified to cause the greatest damage to blood cells, however 
this may be alleviated by improving surface finish on rotating impellers. This modification can 
be easily incorporated into future IPRAC prototypes and is not anticipated to affect overall gas 
exchange performance. Total gas exchange achieved with the IPRAC was ~40% below our 
target CO2 removal rate however, and any modifications that improve gas exchange in future 
prototypes will require additional hemolysis studies. 
Hemocompatibility testing here was limited to red blood cell hemolysis rates. Platelet 
activation or aggregation in response to non-biological surface contact, shear, or stagnation is a 
common pathway of thrombosis and device failure [120]. Housing and fiber materials were 
consistent with those commonly used in oxygenator devices to minimize material effects [97]. 
Surface effects cannot be fully eliminated with exposure to synthetic materials however, and may 
still trigger a biologic response. Impeller washing can help prevent stagnant clot formation, but 
platelet lysis in response to impeller shear can activate coagulation without sufficient 
anticoagulation [121]. Surface bound platelet levels in future impeller systems may be quantified 
as previously described using a lactate dehydrogenase (LDH) assay kit [8, 122]. Imaging of 
bundles under SEM may also reveal development of coagulation networks between fiber layers 
as well as identify platelet adhesion on fiber surfaces.  
Impeller surface polishing was found to reduce impeller/cage associated hemolysis, 
however preventing impeller contact with the surrounding cage would more effectively minimize 
hemolysis. Implementing a system to prevent impeller/cage contact in the existing IPRAC device 
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would be very challenging. A concept for a magnetically levitated shaft was demonstrated here, 
however this approach is not feasible for an intravascular device. Significant magnetic forces 
were also required to stabilize the shaft (Figure 3.3). Elimination of impeller/cage contact could 
be accomplished in an extracorporeal device though replacement of the flexible cage with a 
larger, rigid driveshaft. The anticipated increase in overall device diameter to achieve this would 
be substantial and device flexibility would be compromised, limiting this approach to devices not 
intended for intravascular use. 
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4.0 FEASIBILITY TESTING FOR CO2 REMOVAL AT ULTRA-LOW BLOOD 
FLOWS 
4.1 INTRODUCTION 
Extracorporeal gas exchange circuits have recently become recognized as a last resort option for 
severe lung failure when mechanical ventilation is failing or is not an alternative.  Extracorporeal 
devices respirate blood independently of the lungs, allowing injured tissue to rest and heal [123]. 
The primary complication risks of extracorporeal gas exchange are associated with cannulation, 
exposure of blood to foreign materials, the concomitant requirement for systemic 
anticoagulation, and the stresses induced by mechanical pumping [22]. The degree of risk 
associated with these factors correlates with the extracorporeal blood flow rate necessary for 
treatment [22, 36, 120]. To provide full extracorporeal oxygenation of venous blood requires 
circuit flows up to the full cardiac output (4-7 mL/min) [35, 36]. In contrast, full metabolic CO2 
removal can be achieved at much lower extracorporeal blood flows. CO2 is predominantly 
carried in the form of highly soluble bicarbonate ion that rapidly restores depleting CO2 as it is 
eliminated, and the CO2 dissociation curve is essentially linear and does not saturate like the 
oxyhemoglobin dissociation curve [31, 33, 34]. These differences also provide the opportunity to 
augment CO2 removal efficiency with gas exchanger design features aimed at reducing the 
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thickness of the diffusive boundary layer at the gas exchange surface, where gas transport 
through blood is limited to diffusion [25]. 
The degree of risk associated with extracorporeal lung support is reduced when lower 
blood flows are needed to provide clinically meaningful benefit [36]. The ability to efficiently 
remove CO2 at lower blood flows has motivated use of extracorporeal CO2 removal, or ECCO2R, 
as an alternative or supplement to mechanical ventilation. The two primary clinical indications 
where this objective is feasible are acute exacerbations of chronic obstructive pulmonary disease 
(ae-COPD) and moderate to severe ARDS, where lung protective ventilation strategies are 
necessary but are unable to maintain safe levels of CO2 removal [28, 124]. ECCO2R was shown 
to reduce intubation rates in ae-COPD patients failing less invasive ventilation and assisted in 
weaning from ventilation [3, 4, 66, 69, 70, 72]. Hypercapnia was also managed in moderate 
ARDS patients using ECCO2R to facilitate more protective ventilation strategies by enabling 
reduction of tidal volumes to ≤4 mL/kg without complications [75, 23]. Associated risk remains 
the primary obstacle of ECCO2R adoption in these indications however. Currently approved 
ECCO2R systems can operate at blood flows around 500 mL/min, but still require cannula with 
size greater than 15 Fr [22]. The ability to provide the same levels of CO2 removal at even lower 
flows will enable the use of smaller catheters that are similar in size to commonly used dialysis 
catheters that are 9-14 Fr.  
Work on the IPRAC focused primarily on the development of new approaches to 
maximize gas exchange in a HFM based artificial lung device. Active mixing facilitated by 
rotating impellers yielded the highest CO2 removal efficiency in the IPRAC of any reported 
device. CO2 removal increased by >15-fold in the IPRAC (versus 0 RPM). The only approved 
respiratory assist device with active mixing (Hemolung RAS) increases gas exchange by ≈60%, 
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suggesting impeller mixing may be lucrative for enhancing gas exchange in an extracorporeal 
device [68]. Recognizing the broader potential of this approach, we hypothesized that impeller 
generated active mixing could be utilized in an extracorporeal device.  
The IPRAC impeller technology was adapted to an extracorporeal device to determine if 
clinically significant CO2 removal can be achieved at hemodialysis blood flows. CO2 removal of 
70-160 mL/min has been shown to benefit patients with hypercapnia, which translates to a target 
CO2 removal rate of ≥25-35% metabolic CO2 production (~200-250 mL/min) at normocapnia 
(pCO2 = 45 mmHg) [53, 54]. The device also should maintain an optimal degree of fluid 
washing around the hollow fiber membranes to eliminate regions of stagnation but without 
causing unacceptable levels of blood cell trauma. This chapter reports on the design and bench 
testing of an ultra-low flow ECCO2R device (ULFED) utilizing the rotating impeller concept. 
Feasibility in vitro gas exchange testing was evaluated.  
4.2 MATERIALS AND METHODS 
 
4.2.1 Device Description 
The feasibility prototype of the Ultra-Low-Flow ECCO2R Device (ULFED) (Figure 4.1) has the 
same basic geometry as the IPRAC device described in Section 2.2. Impellers (Crescent design, 
3 blades, 4 mm OD, 10 mm length, spaced 2 mm, 23 total impellers) were fixed to a flexible 
driveshaft (0.042” (1.07 mm) diameter) (SS304V; Heraeus Medical Components, St. Paul, MN). 
Impellers rotate inside a stainless steel safety coil (inner diameter 5 mm) that protects the 
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surrounding fiber bundle. 750 PP fibers (Membrana Celgard x30-240, Wuppertal, Germany) 
were wrapped over the coil for a total surface area of 0.21 m2. The assembly was potted in 
cylindrical acrylic housing (inner diameter 7/8” (22.2 mm)) leaving a small gap between the 
fiber bundle and housing wall (~4 mm). The total fluid priming volume is ~105 mL. Blood 
enters the housing at the center of the fiber bundle through a 3/16” (4.76 mm) stainless steel tube 
used in the potting (see Figure 4.1). Blood exits through a 1/4” (6.35 mm) port on the housing 
opposite the inlet.  
 
 
 
 
Figure 4.1. ULFED feasibility prototype with 750 PP fibers in 7/8” ID acrylic housing. 
 
 
 
The impeller shaft exits the blood compartment at the center of the fiber bundle near the 
blood outlet port and connects to an external DC brushless servomotor (2057-048B; MicroMo 
Electronics Inc., Clearwater, FL). A stainless steel ball-bearing supports the shaft where it 
connects to the motor. The shaft is sealed with an oil seal (400054; SKF, Gothenburg, Sweden) 
next to the bearing. The driveshaft was continuously flushed with a saline infusion line (30 
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mL/hr) that protected seals and bearings from blood backflow up the driveshaft. The fibers 
terminate at each end of the housing in sealed compartments where they enter/exit the device 
through ports on the housing. Sweep gas flows counter-current to blood flow.  
4.2.2 In Vitro Gas Exchange 
CO2 removal performance of the ULFED prototype was evaluated in a single-pass flow loop 
(Figure 4.2) at a hemodialysis blood flow rate of 250 mL/min. The evaluations followed 
ISO 7199:2009 standards for gas exchange testing in blood oxygenators [125]. Filtered and 
heparinized bovine blood (20 U/mL) was collected fresh from the slaughterhouse the day of 
testing. The fluid circuit consisted of a centrifugal blood pump (BPX-80; Medtronic, 
Minneapolis, MN), a commercial oxygenator (Affinity NT; Medtronic, Minneapolis, MN), two 
blood reservoirs connected in parallel, and the ULFED. Blood continuously recirculated at 4500-
5500 mL/min while gas tensions were balanced by the commercial oxygenator to normocapnic 
venous conditions (pCO2 = 45 ± 5 mmHg) using a N2/CO2/O2 gas mixture. Blood temperature 
was maintained at 37 ± 1°C with a heat exchanger integrated into the commercial oxygenator. 
Flow recirculated only to and from the primary reservoir during balancing, while secondary 
reservoir tubing remained clamped. Gas levels in the recirculating loop were monitored with a 
blood gas analyzer (RapidPoint 405; Siemens, Erlangen, Germany) until venous conditions were 
reached. The loop was then converted to single-pass mode for data collection by diverting flow 
to the secondary reservoir and clamping the bypass tubing in parallel to the ULFED. 
Measurements were collected at rotation speeds from 0-34,000 RPM once all measured 
parameters remained stable for ≥2 minutes. A minimum of two measurements were collected at 
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each rotation speed. Blood flow rate was continuously monitored with an ultrasonic flow probe 
(Transonic Systems, Ithaca, NY). 
 
 
 
 
Figure 4.2. Test circuit used to evaluate in vitro gas exchange performance of the ULFED. 
 
 
 
Details and equipment used in the sweep gas pathway match those described in Section 
2.2.3. Pure O2 sweep gas is pulled through fibers counter-current to blood flow at 5.7-6.2 L/min 
by a sealed vacuum pump (N811 KV.45P; KNF Neuberger, Inc., Trenton, NJ, USA). Gas flow 
rate was monitored with a mass flow controller (GR-116-1-A-PV-O2; Fathom Technologies, 
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Georgetown, TX, USA). CO2 in the sweep gas was measured directly with a gaseous CO2 
analyzer (WMA-4; PP Systems, Amesbury, MA, USA). CO2 removal was calculated from the 
fraction of CO2 in the outlet gas and the STP corrected gas flow rate according to Equation 2.1 
(page 30) and normalized for inlet pCO2 per Equation 2.2.  
Performance is reported as the average and standard deviation at CO2 removal at each 
rotation speed for one prototype. A minimum of two measurements were recorded at each 
rotation speed. A second prototype was fabricated and tested at select rotation speeds (10,000 – 
30,000 RPM) at a later date to verify performance. 
Blood samples were analyzed for hemolysis prior to and following gas exchange testing 
of the first prototype. An approximate normalized index of hemolysis (NIH) was calculated from 
measurements as described in Section 3.2.1 to estimate cell damage prior to conducting formal 
hemolysis testing. No formal hemolysis testing was conducted on the ULFED prototype.   
4.3 RESULTS 
Normalized CO2 removal rates of each ULFED prototype tested are shown in Figure 4.3. Each 
device displayed a linear relationship between RPM and CO2 removal at speeds ≥10,000 RPM.  
The first device achieved a maximum normalized CO2 removal rate of 75.3 ± 0.3 mL/min at the 
highest rotation speed evaluated (34,000 RPM). Impeller generated active mixing overall 
contributed to ~225% enhanced CO2 removal in the ULFED versus 0 RPM.  
Measured NIH of the ULFED prototype over the ~6 hour gas exchange test was ~2.7 
g/100L. Hemolysis in the ULFED is significantly greater than generally accepted values (≤0.05 
g/100 L) for blood pumps and oxygenators. We suspect the highest RPM would contribute to the 
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greatest rate of cell damage, but these speeds were only maintained for short periods (~10 
minutes) during data collection.   
 
 
 
 
Figure 4.3. In vitro CO2 removal of ULFED feasibility prototype versus RPM. CO2 removal 
rates were normalized to an inlet pCO2 = 45 mmHg.  
 
 
4.4 DISCUSSION 
Extracorporeal CO2 removal (ECCO2R) systems may be used in combination with non-invasive 
and protective ventilation to improve outcomes in hypercapnic respiratory failure. An ECCO2R 
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device operating at conditions comparable to renal hemodialysis would allow adaptation of 
minimally invasive cannulation strategies used in dialysis. A minimally invasive ECCO2R 
system would also simplify circuit management, and has potential to be used with dialysis 
equipment or spliced into existing dialysis circuitry. Impeller technology from the IPRAC was 
adapted for a new ECCO2R device and demonstrated clinically significant CO2 removal rates of 
75 mL/min at 34,000 RPM could be achieved at hemodialysis blood flows (250 mL/min). 
Hemolysis measurements taken during gas exchange tests showed an NIH value of 2.7 g/100 L, 
a rate >10 times greater than acceptable values. Clinically significant gas exchange rates at 
dialysis flow rates were demonstrated but high hemolysis indicates a redesign focused on 
minimizing cell damage is necessary.  
Invasive mechanical ventilation can exacerbate lung injuries using settings (tidal volumes 
~12 mg/kg) that decarbonate the blood enough to prevent hypercapnia [15]. CO2 removal at ≥65 
mL/min (~25-35% metabolic CO2 production) can correct pH and pCO2 in hypercapnic patients 
to avoid transition to high tidal volume invasive ventilation [53, 54]. Intubation can be avoided 
with this level of support for ae-COPD and can aid in early extubation for patients already on 
ventilation [3, 66, 72, 77, 126, 127]. Early CO2 removal therapy for these patients is emphasized 
given that mortality rates for patients transitioned to invasive ventilation after failing non-
invasive ventilation are higher than if they had been intubated immediately [16]. CO2 
management also allows ventilator settings to be lowered to safer levels (tidal volumes ≤3-4 
mL/kg) in ARDS that reduces risk of over-distending pulmonary tissue [23, 128, 129]. The CO2 
removal prototype here achieved CO2 removal at ~30-37% metabolic CO2 production, matching 
or exceeding levels with demonstrated clinical benefit.  
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An ultra-low-flow ECCO2R device (ULFED) operating at 250 mL/min makes CO2 
removal therapy comparable to dialysis and simplifies cannulation strategies. Efficient gas 
exchange allows fiber surface area to be minimized. Target CO2 removal rates were achieved 
with 0.21 m2, which is <40% of the surface area used in approved ECCO2R systems [54]. High 
washing due to impeller mixing also eliminates concerns of stagnation and associated clotting, 
potentially allowing anticoagulation requirements to be reduced. Existing ECCO2R systems use 
large fiber surface areas to achieve target CO2 removal rates. Passive flow devices (i.e. having no 
active mixing mechanism) with CO2 removal performance matching the ULFED have surface 
areas >1.3 m2 (Novalung iLA Activve with iLA or XLung, Estor Prolung, Maquet PALP) [71, 
78]. Low surface area devices (<0.5 m2) that report lower CO2 removal rates (<60 mL/min) and 
operate at low blood flows (<300 mL/min) are available or in development, including the 
Novalung iLA Activve with MiniLung or MiniLung Petite, and the Gambro-Baxter PrismaLung 
[80]. The Hemolung RAS has demonstrated clinical benefit to patients using a relatively low 
surface area design (0.59 m2) and flows (350-550 mL/min) in part due to integrated active 
mixing components [22, 53]. 
Hemocompatibility testing was not formally conducted on the ULFED based on 
preliminary hemolysis data collected during gas exchange testing. Rotation speeds up to 34,000 
RPM were tested in the ULFED that may have contributed to higher cell damage than seen in the 
IPRAC, which was tested only at 20,000 RPM. The ULFED was only tested at the maximum 
speed, where hemolysis is logically greatest, for short periods (~10 minutes). Hemolysis 
associated with the ULFED at maximum speed for an extended duration would likely be greater 
than the measured NIH of ~2.7 g/100L. In vitro hemolysis testing on the IPRAC revealed that 
contact between impellers and the surrounding cage was a significant source of cell damage. 
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When the cage and fibers were removed from a modified IPRAC as described in Chapter 3.0, 
hemolysis was within acceptable ranges (NIH < 0.05 g/100 L). Polishing impeller surfaces may 
eliminate cell damage associated with impeller/cage contact, but any feature contributing to 
measureable hemolysis are not ideal. Impeller/cage related cell damage in future ULFED 
prototypes can instead be eliminated entirely by preventing contact between impellers and the 
safety cage. This is accomplished in a redesign of the ULFED described in Chapter 5.0, where 
the flexible driveshaft is replaced with a larger diameter rigid shaft.  
The ULFED was tested at rotation speeds greater than those evaluated in the IPRAC 
(34,000 versus 20,000 RPM). The IPRAC performance curves (RPM versus CO2 removal) 
observed and reported by Mihelc et al. suggest it may also benefit from higher rotation speeds 
[5]. Gas exchange in the ULFED prototype at the maximum 34,000 RPM was 30% greater than 
at 20,000 RPM. We may therefore expect to see IPRAC CO2 removal rates improve from 40 
mL/min (see Chapter 2.3.4) to 50-55 mL/min if evaluated at this higher rotation speed. 
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5.0  ULFED DESIGN MODIFICATIONS AND IN VITRO PERFORMANCE 
CHARACTERIZATION 
Sections from the following chapter are included in a manuscript currently under review for 
publication. The manuscript reports in vitro performance of only the top performing ULFED 
design discussed below, including gas exchange and hemolysis results. Topics omitted from the 
manuscript include the theoretical scaling analysis (Sections 5.2.1 and 5.3.1), comparison of 
bundle aspect ratio and impeller length on gas exchange performance (Sections 5.3.3 and 5.3.4), 
and the computational gas exchange model (Section 5.2.4).    
5.1 INTRODUCTION 
Clinically significant levels of CO2 removal at hemodialysis flow rates was demonstrated 
with an ULFED prototype that closely resembled the IPRAC fitted to standalone housing. 
Hemocompatibility concerns associated with high rotation speeds required in the ULFED 
prototype and design features irrelevant to an extracorporeal device motivated additional work in 
this area and the design of a new impeller device optimized for the application. This chapter 
discusses design improvements to the ULFED that tailor its use for extracorporeal support. 
Elimination of shaft flexibility removes a potential source of cell trauma by preventing 
contact between the impellers and the surrounding stainless steel coil, as well as heat generated 
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from friction where the shaft enters the blood compartment. Stabilizing the existing 0.042” 
diameter shaft at 34,000 RPM would be extremely challenging due to harmonic instabilities 
during rotation that occur with a small diameter shaft (discussed further in Section 5.3.1 below). 
The shaft diameter will therefore be increased to provide more stability according to a theoretical 
analysis of critical shaft rotation speed. The bundle and impeller diameters will also be scaled 
proportionally to maintain geometric similarity between the current and proposed design.  
Gas exchange in the IPRAC was increased when spacing between impellers was reduced. 
A potential mechanism is that the number of recirculation regions in the bundle increased as a 
direct result of adding more impellers. Each impeller is associated with a distinct region of flow 
recirculation in and out of the fiber bundle, and increasing the density of recirculation regions 
may increase active mixing intensity and gas exchange. The effect of increasing the number of 
impellers (by reducing length) on gas exchange in the ULFED was investigated to evaluate this 
mechanism. The effects of fiber bundle geometry on gas exchange were also evaluated. The 
IPRAC bundle design was restricted by vascular dimensions that are irrelevant for an 
extracorporeal device. Changes to the bundle aspect ratio (length and diameter) affect fiber 
locations relative to the impellers and could be optimized to maximize efficiency. For example 
we hypothesize that lengthening the bundle will increase the surface area of fibers in the first 
layer of the bundle where we suspect active mixing intensity is greatest, but if this parameter has 
little impact a shorter bundle would simplify fabrication, require less impellers, and reduce 
priming volume.  
This chapter reports on the redesign and testing of an ULFED for operation at 
hemodialysis blood flows (250 mL/min). A theoretical approach is described to estimate a range 
of appropriate design scaling factors to ensure shaft stability during rotation. The effects of 
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impeller length and bundle design were also investigated in the ULFED. We hypothesized that 
bundle geometry and impeller length are parameters that can be optimized to maximize 
performance. ULFED prototypes were tested in vitro for CO2 removal performance. In vitro 
hemolysis testing was conducted using the top performing ULFED from gas exchange 
experiments against a clinically approved oxygenator control. In parallel we conducted a 
computational analysis using a previously verified mathematical model for CO2 removal to 
estimate the performance enhancement gained by impeller generated active mixing.  
5.2 METHODS 
5.2.1 Determination of Theoretical Scaling Factor 
The primary objective of the scaling analysis is to determine an appropriate shaft size for the 
ULFED so that rotational stability is maintained during operation. The shaft diameter, impellers, 
and bundle inner diameter will each be scaled by the same factor to maintain geometric 
similarity to the feasibility prototype.  
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Figure 5.1. Theoretical shaft deflection equations for ULFED driveshaft. 𝜹𝒊𝒎𝒑 is the shaft 
deflection associated with each impeller, 𝑳𝒔𝒉𝒂𝒇𝒕 is the shaft length between proximal bearings 
and distal supports, 𝒙 is the distance to the deflection point (equal to ½ Lshaft), 𝑭𝒊𝒎𝒑 is the force 
associated with the mass of impellers along the shaft (𝝆𝒊𝒎𝒑𝒈𝑽𝒊𝒎𝒑), 𝝆𝒊𝒎𝒑 is the impeller material 
density (DSM Somos Watershed XC11122, 1.12 g/cm3), 𝑬 is the modulus of elasticity of the 
316L stainless steel driveshaft (1.89e11 kg/m/s2), 𝑰 is the moment of inertia of the driveshaft, 
𝝆𝒔𝒉𝒂𝒇𝒕 is the 316L stainless steel driveshaft density (7.863 g/cm
3), 𝑫𝒔𝒉𝒂𝒇𝒕 is the driveshaft 
diameter, and 𝒘𝒔𝒉𝒂𝒇𝒕 is the weight of the driveshaft in N/m. 
 
 
 
The minimum shaft diameter for future ULFED prototypes is based on the shaft’s 
theoretical critical rotation speed, which is an approximation of the minimum rotation rate that 
excites the shaft’s natural frequency. Operation at or above the critical speed (𝑁𝑐) causes system 
vibration and instability, so common practice suggests operating speeds should be ≤ 0.75𝑁𝑐. We 
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are targeting operating speeds ≤ 0.5𝑁𝑐 for additional safety and to account for small errors due to 
estimations in the analysis. The critical rotation speed is calculated as 
 
𝑁𝑐 =
30
𝜋
√
𝑔
𝛿𝑠𝑡
 5.1 
Where 𝑁𝑐  is expressed in RPM, 𝑔 is the gravitational constant (9.81 m/s
2), and 𝛿𝑠𝑡 is the 
maximum static shaft deflection due to gravitational forces at rest (meters). The shaft deflection 
is a function of the shaft diameter and is estimated from beam deflection equations that account 
for impeller and shaft weights as shown in Figure 5.1.  
The beam was assumed to be fixed at one end (proximal end attached to motor) and 
supported distally. The number and mass of impellers was accounted for in deflection equations. 
Impeller length and diameter are scaled proportionally with the shaft to maintain geometric 
similarity so less impellers fit on the shaft as the scaling factor increases. The mass of individual 
impellers in the analysis was estimated based on anticipated volume in SolidWorks and raw 
material density. The total shaft deflection distance at rest is the sum of all deflections, 𝛿𝑠𝑡 =
𝛿𝑠ℎ𝑎𝑓𝑡 + ∑ 𝛿𝑖𝑚𝑝,𝑖
# 𝑖𝑚𝑝𝑠 , where the maximum deflection is assumed to be at the center of the 
shaft. Scaling factors of 1-5 were evaluated, where a scaling factor of 2 represents a shaft 
diameter of 2×0.046”, i.e. double the IPRAC shaft diameter. The analysis was performed for 
exact impeller and bundle scaling factors but shaft diameters were limited to readily available 
sizes that could be stock ordered (e.g. 3/16”, ¼”, etc.). The closest available shaft size was used 
for all evaluated scaling factors.  
Pumping ability of geometrically similar impellers will also increase as a function of 
diameter. Larger impellers will therefore require lower rotation speeds to achieve the same fluid 
velocities in the fiber bundle. We hypothesized that gas exchange will be comparable in the 
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scaled up ULFED if average fluid velocity in the fiber bundle is matched to the feasibility 
prototype [52, 130]. Fluid velocity leaving the blade tip was assumed to scale proportionally with 
impeller diameter. A decrease in fluid velocity was accounted for as fluid moves radially 
outward away from impellers (proportional decrease with radius). Bundle thickness was 
estimated using Archimedean spiral length equations to approximate the number of fiber wraps 
for any given scaling factor. Critical rotation speeds at each scaling factor were compared to the 
estimated rotation speed for scaled devices.  
5.2.2 Device Description 
The new ULFED prototype (Figure 5.2) shares the same basic design as the feasibility prototype 
discussed in section 4.2.1 and the IPRAC in section 2.2.1. A series of rotating impellers are fixed 
on a rigid stainless steel drive shaft and surrounded by an annular bundle of polypropylene (PP) 
hollow fiber membrane fibers (300 μm diameter, total gas exchange surface area 0.42 m2) 
(Membrana Celgard x30-240, Celgard, Wuppertal, Germany) inside a cylindrical acrylic 
housing. Impellers (Figure 5.3) were designed in SolidWorks (Concord, MA, USA) and 
fabricated at the University of Pittsburgh Swanson Center for Product Innovation (Pittsburgh, 
PA, USA) from a hydrophobic epoxy resin (Watershed XC11122; DSM Somos, Sittard, 
Netherlands) using stereolithography (SLA). The Radial Tangent (3 blades) impeller design 
previously evaluated in the IPRAC (section 2.2.2) was chosen for future ULFED prototypes for 
its similarity to established centrifugal pump vane designs.  
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Figure 5.2. ULFED prototype and cross-sectional schematic. Schematic shows arrangement of 
impellers surrounded by safety coil and annular fiber bundle. 
 
 
 
 
Figure 5.3. Distal end of ULFED driveshaft showing impellers and bearings. Impellers/bearings 
from Device 3 – (4 cm length, 11.7 mm diameter), ceramic pivot bearing, and UHMWPE 
bearing cup. 
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Three ULFED prototypes were fabricated to evaluate the impact of bundle aspect ratio on 
gas exchange. Impellers were fabricated with axial lengths according to the scaling analysis, and 
at 1/4 of the scaled length to evaluate the effects of impeller length (recirculation regions) in the 
bundle. Spacing between impellers was set to 1/5th impeller length to match the top performing 
arrangement from IPRAC testing (Section 2.3.1).  Each shaft was fit with the maximum number 
of impeller that would fit in the available space. Specific device dimensions were determined 
through the scaling analysis and are presented in the Results section below in Table 5.2.  
The impeller drive shaft extends out of the blood pathway and is sealed (400054; SKF, 
Gothenburg, Sweden) and supported by bearings (Ceramic R3; Ortech, Inc., Sacramento, CA). 
An external DC brushless servomotor (4490 H 048B; MicroMo Electronics, Inc., Clearwater, 
FL) drives shaft rotation. Heparinized saline (20 U/mL) is continuously infused along the shaft at 
30 mL/hr to lubricate and protect the seal and bearing from blood backflow up the driveshaft. 
The shaft is supported distally using a custom pivot bearing (ceramic pin (MSC Industrial 
Supply, Melville, NY) nested in an ultra-high molecular weight polyethylene cup (UHMWPE; 
Orthoplastics, Lancashire, UK)) shown in Figure 5.3.  
Blood ports on the proximal and distal ends of the house are 1/4” [6.35 mm]. Blood 
enters at the port distal to the motor, and exits at the opposite end. The location of the inlet port 
was relocated to the housing in the ULFED versus the previous prototype for ease of fabrication. 
Pure O2 sweep gas is pulled through fibers under vacuum, counter-current to the direction of 
blood flow.  
Three ULFED prototypes were fabricated with different bundle aspect ratios. Two 
additional prototypes were fabricated with the bundle aspect ratio that performed highest in gas 
exchange testing for repeatability and hemolysis testing. 
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5.2.3 In Vitro Gas Exchange  
CO2 removal performance of ULFED prototypes were evaluated according to methods detailed 
in Section 4.2.2 (page 67) following established ISO 7199:2009 standards [125]. Blood 
continuously recirculated until normocapnic venous conditions (pCO2 = 45 ± 5 mmHg) were 
reached. ULFED gas exchange measurements were collected at dialysis blood flows (250 
mL/min) at rotation speeds from 0-5,000 RPM once all measured parameters remained stable for 
≥2 minutes. Pure O2 sweep gas was pulled through fibers counter-current to blood flow at 8.0 
L/min.  
A minimum of two measurements were collected at each rotation speed. Each of the three 
ULFED prototypes were evaluated with both impeller configurations (full length and ¼ length 
impellers). Repeatability testing was conducted with two newly fabricated ULFED prototypes 
after identifying the highest performing bundle/impeller configuration. Failure in the gas 
pathway in one of the new prototypes limited repeatability testing to a single device. CO2 
removal of the two matching ULFED prototypes are reported as average and standard deviation 
of performance at each rotation speed.  
5.2.4 Computational Gas Exchange Model 
The ULFED fiber bundle design is not optimized for uniform flow in the fiber bundle in the 
absence of impeller mixing. To estimate the CO2 removal enhancement associated with active 
mixing versus development of uniformly distributed flow in the fiber bundle we use a 
computational model developed and validated previously by our group to predict CO2 removal in 
passive flow conditions. The mathematical model described by Svitek and Federspiel [101] uses 
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an empirical mass transfer correlation for a geometrically similar annular fiber bundle, 
incorporating a "facilitated diffusivity" to account for CO2 transport in blood in the form of 
bicarbonate ion. The computational model was used exclusively for interpretation of gas 
exchange results and was not verified experimentally. 
Derivation of mass transfer equations for O2 and CO2 in blood by membrane oxygenators 
have been reported by several investigators [51, 101–103, 131–134]. The overall mass balance is 
the same for each gas, the major differences being the definition of terms in the mass transfer 
correlation. The model assumes that gas side and membrane wall resistances are negligible 
because resistance to gaseous diffusion in blood is significantly greater [52]. Total CO2 in the 
blood is either dissolved (7%), bound to hemoglobin (23%), or hydrated to bicarbonate ion 
(HCO3) (70%) in a reversible reaction catalyzed by carbonic anhydrase enzyme within red blood 
cells [33]. Conversion between CO2 and HCO3 is many times greater than diffusion and 
convection in blood so the model assumes that dissolved CO2 is always in equilibrium with 
hemoglobin bound and bicarbonate forms. The physical constants used for CO2 in the model 
analysis are summarized in Table 5.1. 
The overall mass balance of CO2 in the blood is:  
 𝑄
𝑑𝐶
𝑑𝑟
= 2𝜋𝑟𝐿𝑘𝑎𝑣𝛥𝑃 5.2 
where 𝑄 is the blood flow rate perpendicular to the fiber bundle, 𝐶 is dissolved and chemically 
bound gas concentration in blood, 𝑟 is the radial coordinate, 𝐿 is bundle thickness, 𝑘 is the mass 
transfer coefficient, 𝑎𝑣 is the membrane surface area per bundle volume, and Δ𝑃 is the gaseous 
pressure difference across the membrane wall, which is assumed to be constant from fiber inlet 
to outlet. Molecular diffusion of CO2 is neglected from the mass balance since it is small relative 
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to convective transport. CO2 concentration is estimated from an empirical fit of the CO2 
dissociation curve, relating partial pressure to total CO2 (mL CO2 /mL blood):  
 𝐶𝐶𝑂2 = 𝑞𝑃𝐶𝑂2
𝑡  5.3 
where 𝑞 and 𝑡 are constant regression parameters with values 0.128 and 0.369 [34].  
The overall mass balance can be rearranged for CO2 partial pressure as a function of 
radial displacement through the fiber bundle:  
 
𝑑𝑃
𝑑𝑟
= −
2𝜋𝑟𝑘𝑎𝑣𝐿
𝑄𝜆
Δ𝑃 5.4 
where λ is the effective solubility of both dissolved and bound CO2:  
 𝜆 =
𝜕𝐶𝐶𝑂2
𝜕𝑃𝐶𝑂2
= 𝑞𝑡𝑃𝐶𝑂2
𝑡−1 5.5 
The mass transfer coefficient 𝑘 is solved from an analogous mass transfer correlation for 
heat transfer perpendicular to a bundle of tubes [51, 102, 135]:  
 𝑆ℎ = 𝑎𝑅𝑒𝑏𝑆𝑐1/3 5.6 
where 𝑆ℎ is the Sherwood number, 𝑅𝑒 is the Reynolds number, 𝑆𝑐 is the Schmidt number, and 
the constants 𝑎 and 𝑏 are empirically derived values based on the fiber bundle geometry. The 
Reynolds number relates inertial to viscous forces, defined as 𝑅𝑒 = 𝜌𝑣𝑑ℎ/𝜇, where 𝜌 is the fluid 
density, 𝑑ℎ is the hydraulic diameter characteristic of the fiber packing (equal to hollow fiber 
diameter for packed beds with porosity >0.5), 𝑣 is the superficial fluid velocity in the bundle 
(𝑄/2𝜋𝑟𝐿), and 𝜇 is the dynamic fluid viscosity. The Schmidt number relates momentum to mass 
diffusivity, and is defined as 𝑆𝑐 = 𝜈/𝐷, where 𝜈 is kinematic viscosity, and 𝐷 is diffusivity of 
the dissolved gas. The Sherwood number relates molecular to convective mass transfer 
resistance, defined as 𝑆ℎ = 𝑘𝑑ℎ/𝛼𝐷 where 𝛼 is CO2 solubility in fluid.  
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Table 5.1. Physical constants used in passive flow gas exchange model. 
Parameter Description Value 
 𝑄 Blood flow rate 250 mL/min 
 𝜌  Blood fluid density 1.06 g/mL 
 𝑑ℎ Hydraulic diameter 0.03 cm 
 𝜇 Dynamic viscosity of blood 3.4 cP 
 𝛼 Solubility of CO2 in blood 6.62e-4 mLCO2 mLblood⁄ /mmHg 
 𝐷𝐶𝑂2 Diffusivity of CO2 in blood 7.39e-6 cm
2/s 
 𝐷𝐻𝐶𝑂3 Diffusivity of HCO3 in blood 4.62e-6 cm
2/s 
 𝑝𝐶𝑂2
𝑖𝑛 Inlet CO2 partial pressure 45 mmHg 
 𝑝𝐶𝑂2
𝑓𝑖𝑏𝑒𝑟𝑠
 Average sweep gas CO2 partial pressure 2 mmHg 
 
 
 
 
A facilitated diffusivity (𝐷𝑓) term must be used in the Sherwood number for blood, which 
accounts for diffusion of both bicarbonate ion and dissolved CO2. An effective diffusivity (𝐷𝑒𝑓𝑓) 
term is then used in the Schmidt number that accounts for chemically bound forms of CO2. Each 
is defined by Svitek and Federspiel [101] and simplify to:  
 𝐷𝑓 = 𝐷𝐶𝑂2 +
𝐷𝐻𝐶𝑂3
𝛼
𝜆 5.7 
 𝐷𝑒𝑓𝑓 =
𝐷𝑓
1 +
1
𝛼 𝜆
 5.8 
where 𝐷𝐶𝑂2 and 𝐷𝐻𝐶𝑂3 are the diffusivities of CO2 and bicarbonate ion in blood.  
The above definitions and equations can be combined and rewritten to yield the mass 
transfer coefficient:  
 𝑘 = 𝑎𝛼𝑑ℎ
𝑏−1 (
𝑄
2𝜋𝑟𝐿
)
𝑏
(𝐷𝐶𝑂2 +
𝐷𝐻𝐶𝑂3
𝛼
𝜆)
2/3
(1 +
1
𝛼
𝜆)
1/3
𝜈1/3 −𝑏 5.9 
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Equation 5.9 can be inserted into Equation 5.4 and integrated to determine the partial 
pressure profile through the annular fiber bundle. The resulting profile can then be used together 
with Equation 5.3 to calculate the total CO2 removed from the system: 
 𝑉𝐶𝑂2 = 𝑄𝑏𝑙𝑜𝑜𝑑𝛥𝐶 5.10 
where Δ𝐶 is the CO2 concentration difference between the blood entering and exiting the bundle. 
The constants 𝑎 and 𝑏 are unique to bundle design and are typically determined 
experimentally in gas exchange tests in water [51, 60, 101–103, 131–135]. Previous researchers 
have had success using the average of reported values for various devices however [130]. The 
ULFED bundle was designed with no expectation of achieving uniform flow through the fiber 
bundle under passive flow conditions (i.e. 0 RPM). Calculating mass transfer correlation 
constants from water experiments are therefore not feasible. The values measured by Svitek and 
Federspiel (𝑎= 0.54, 𝑏= 0.42) were used to predict CO2 removal to within 10% of experimental 
performance in two annular bundle designs. The ULFED design is comparable to the described 
device, having geometrically similar bundles, matching fiber surface area, and similar bundle 
porosity. Predicted flow in the ULFED also has estimated Reynolds (≈1–2) and Peclet (≈400–
500) numbers within the range previously evaluated (Re ≈ 1–8, Pe ≈ 400–3500) in water. Other 
studies have reported these values in the range of 𝑎 = 0.12–0.71 and 𝑏 = 0.32–1 for blood 
oxygenators. Model calculations were conducted using 𝑎 and 𝑏 values from the geometrically 
similar bundle design. Calculations were also performed using conservative coefficient values 
that would yield the highest predictions among all oxygenators.  
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5.2.5 In Vitro Hemolysis Testing 
Filtered and heparinized bovine blood (20 U/mL) was collected fresh from the slaughterhouse 
the day of testing per ASTM standards (F1841-97) [115]. The gas exchange loop was modified 
for hemolysis testing by removing the bypass tubing parallel to the ULFED, the commercial 
oxygenator, the secondary reservoir, and the ULFED gas pathway components. A reasonable 
cannula for the target 250 mL/min of blood flow (13 Fr Avalon Elite DLC 10013; Maquet, 
Rastatt, Germany) was included in the circuit so overall hemolysis reflected that of a clinical 
setup. Blood (1000 mL) was continuously recirculated with a pediatric centrifugal pump 
(PediMag; Thoratec, Pleasanton, CA) for 3 hours. The reservoir was submerged in a heated 
water bath to maintain a circuit temperature of 37°±1°C. ULFED rotation was set to the 
minimum speed necessary where CO2 removal did not differ significantly from the maximum 
rate achieved. A second ULFED circuit configuration evaluated performance using a 
hemodialysis controller roller pump (Prisma; Baxter, Deerfield, IL) and cannula. A larger bore 
14 Fr, 15 cm dialysis cannula (AK-22142-F; Teleflex, Morrisville, NC) was used in the second 
circuit due to availability of parts recommended for the target blood flows. 
A control circuit was tested to evaluate ULFED hemolysis against an approved low-flow 
blood oxygenator (Minimax Plus; Medtronic, Minneapolis, MN). Blood flow in the control loop 
was maintained at the minimum rate necessary (1250 mL/min) to match ULFED CO2 removal 
performance according to the manufacturer [136]. Pump (BP-50; Medtronic, Minneapolis, MN) 
rotation speed in the loop was maintained at 2100-2200 RPM against 180 mmHg to simulate 
inclusion of cannula recommended for use at the target blood flows (14 Fr Biomedicus 96820-
014 venous, 12 Fr Biomedicus 96820-012 arterial) [137, 138]. Pressure against the pump was 
adjusted using a Hoffman clamp on ULFED outlet tubing and continuously monitored with a 
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differential fluid pressure transducer (PX771-025DI; Omega Engineering, Inc., Stamford, CT) 
across the pump. All other components and conditions were consistent between circuits. All 
three ULFED prototypes fabricated for gas exchange testing were evaluated for hemolysis in 
both circuit configurations, as the gas pathway failure observed in one prototype did not interfere 
with hemolysis testing. 
Samples were drawn every 30 minutes to measure hematocrit (HCT) and plasma free 
hemoglobin (pfHb). Plasma was isolated from whole blood in two centrifuge spins (15 minutes 
at 0.8 g, 10 minutes at 7.2 g), and absorbance at 540 nm was measured spectrophotometrically 
(Genesys 10S UV-Vis; Thermo Scientific, Waltham, MA). PfHb concentration was calculated 
from absorbance using a standard curve developed from a linear-fit of serially diluted whole 
blood with 100% hemolysis versus absorbance [116]. 
The Normalized Index of Hemolysis (NIH) was calculated for circuit comparisons:  
 𝑁𝐼𝐻 (𝑔/100𝐿) = Δ𝑝𝑓𝐻𝑏 × 𝑉 ×
100 − 𝐻𝐶𝑇
100
×
100
𝛥𝑡 × 𝑄
 (11) 
 
Where 𝑁𝐼𝐻 = normalized index of hemolysis in grams of hemoglobin released into the 
blood per 100 L of flow through the circuit (g/100 L); Δ𝑝𝑓𝐻𝑏 = increase in pfHb over the 
sampling time interval (g/L); 𝑉 = circuit volume (L); 𝐻𝐶𝑇 = hematocrit (%); Δ𝑡 = sampling time 
interval (min); 𝑄 = average blood flow rate (L/min). A time-of-therapy normalized index was 
also calculated, since the NIH equation does not reflect total hemolysis returned to a patient in 
the context of treatment duration. Flow rate normalization in the NIH equation is eliminated in 
the new Therapeutic Index of Hemolysis (TIH) calculation to indicate the total grams of 
hemoglobin released to the blood per 100 minutes of therapy (g/100min):  
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 𝑇𝐼𝐻 (𝑔/100𝑚𝑖𝑛) = Δ𝑝𝑓𝐻𝑏 × 𝑉 ×
100 − 𝐻𝐶𝑇
100
×
100
𝛥𝑡
 (12) 
 
5.2.6 Statistics  
All statistical comparisons were conducted in SPSS (IBM, Armonk, NY). Mean maximum gas 
exchange rates and performance curves were analyzed with a two-way ANOVA to identify 
specific design parameters or interactions that significantly affected performance (bundle length, 
bundle diameter, impeller length). A one-way ANOVA with Tukey HSD post hoc testing was 
used to compare removal rates at each RPM of the top performing device after data satisfied 
assumptions of homogeneity of variance, normality, and independence. RPM comparisons were 
used to identify the minimum speed necessary to achieve statistically equivalent performance to 
the maximum CO2 removal rate. The determined rotation speed for that device was used for 
subsequent hemolysis testing. Mean NIH values were compared using a one-way ANOVA with 
Tukey HSD post hoc test after satisfying relevant assumptions. TIH data violated the assumption 
of homogeneity of variance via Levene’s Test, and means were compared with Welch’s F test. 
Subsequent Games-Howell post-hoc tests were used for between group comparisons of means. 
All comparisons of means were considered significant at the level p<0.05.  
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5.3 RESULTS 
5.3.1 Scaling Factor Analysis and Device Dimensions 
Figure 5.4 shows the estimated critical rotation speed (0.5𝑁𝑐) of the driveshaft and estimated 
rotation speed necessary for prototypes versus scaling factors. The critical speed increases with 
scaling factor due to the increasing diameter of the driveshaft. The curve “steps” upward with 
scaling factor since the driveshaft diameter in our analysis was restricted to the closest available 
parts (e.g. drive shafts with diameters 5/32”, 4 mm, 3/16”, etc.). Small fluctuations in critical 
rotation speed between “steps” are associated with the increasing weight of impellers as each 
increases in size (slightly decreasing 𝑁𝑐) and decreasing number of impellers as less can fit on 
the shaft (from 23 impellers at scaling factor = 1 to 4 impellers at scaling factor = 5).  
The curve showing required rotation speed to match average fluid velocity in the bundle 
of the feasibility prototype decays with scaling factor. The generated fluid velocity increases 
with impeller diameter, so lower speeds are necessary to achieve the same fluid velocity through 
the bundle. The relative distance between impellers and the bundle midpoint also decreases with 
increasing scaling factor since less fiber wraps are necessary in a larger diameter bundle. These 
factors contribute to the nonlinear decay of the required speed curve. The intersection of the two 
curves is the minimum estimated scaling factor where critical speed matches or exceeds 
necessary rotation speed. The region spanning these curves shaded in red in Figure 5.4 represent 
the range of acceptable scaling factors estimated for the redesigned ULFED. A scaling factor of 
3.95 was chosen for the new ULFED dimensions based on availability of parts and one ULFED 
prototype was built to these dimensions. Two other prototypes were fabricated having reduced 
fiber length (Device 2) or reduced bundle diameter (Device 3) to evaluate bundle geometry 
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effects on gas exchange. Design dimensions of each ULFED prototype are summarized in Table 
5.2. 
 
 
 
 
 
Figure 5.4. Results of ULFED scaling factor analysis. Plot shows estimates of theoretical critical 
speed (0.5𝑁𝑐) at various impeller scaling factors (green) and estimated rotation speed at each 
scaling factor required to match the average superficial fluid velocity in the fiber bundle based 
on impeller blade tip velocity (blue). The target range of scaling factors are shaded in red. The 
chosen baseline scaling factor for the ULFED prototype (3.95) is marked in black. 
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Table 5.2. Dimensions of ULFED Test Devices.  
 Device 1 Device 2 Device 3 
 Fiber Bundle Length 30 cm 16.9 cm 30 cm 
 Bundle/Impeller/Shaft Scaling Factor 3.95 3.95 2.7 
 Drive Shaft Diameter 3/16” [4.76 mm] 3/16” [4.76 mm] 3/16” [4.76 mm] 
 Annular Bundle Inner Diameter 21.3 mm 21.3 mm 14.4 mm 
 Annular Bundle Outer Diameter 28.5 mm 31.3 mm 22.8 mm 
 Bundle Thickness 3.6 mm 5.0 mm 4.2 mm 
 Impeller Diameter 15.8 mm 15.8 mm 11.7 mm 
 Estimated Priming Volume 240 mL 135 mL 240 mL 
Impeller Configuration 1 (4 cm impeller length, 0.8 cm shaft gap) 
 Number of Impellers 6 3 6 
Impeller Configuration 2 (1 cm impeller length, 0.2 cm shaft gap) 
 Number of Impellers 23 12 23 
 
 
 
 
5.3.2 In Vitro Gas Exchange 
Figure 5.5 shows the CO2 removal rate of Device 3 as a function of rotational speed for both 
impeller configurations. Performance curves shown in Figure 5.5 are representative of trends in 
all devices, as well as the relationships between each impeller arrangement. Maximum CO2 
removal rates for each device are summarized in Figure 5.6. A sharp increase in CO2 removal 
occurred between 0-2,000 RPM in all devices before subsequently leveling off at higher speeds. 
The maximum normalized CO2 removal rates ranged from 57-75 mL/min, where Device 3 with 
4 cm impellers achieved the highest rate of 75.1 ± 1.1 mL/min at 5,000 RPM. Performance at 
4,000 RPM in the same device did not differ significantly from the maximum rate however (74.1 
± 3.3 mL/min, p=0.99). 
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Figure 5.5. Example of ULFED gas exchange performance curves versus RPM (Device 3 with 
each impeller configuration shown). Error bars represent one standard deviation of measured 
𝑽𝑪𝑶𝟐
∗  at each rotation speed. 
5.3.3 Bundle Aspect Ratio Effects 
Maximum performance with both impeller configurations was 26–31% greater with the reduced 
bundle diameter in Device 3 (maximum 𝑉𝐶𝑂2
∗  = 75.1 ± 1.1 mL/min, n=2 prototypes) than Device 
1 (maximum 𝑉𝐶𝑂2
∗  = 60.1 ± 3.9 mL/min) (all p<0.05). Gas exchange performance curves for 
Device 3 were significantly greater (p<0.05) than the larger bundle diameter Device 1 when 
tested with both 1 cm and 4 cm long impellers in 3 of 4 comparisons. The exception being 
Device 3, impeller configuration 2 versus Device 1, impeller configuration 2, where the two 
were not found to differ significantly.  
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Figure 5.6. Maximum in vitro normalized CO2 removal rate of ULFED prototypes in blood. 
Error bars represent one standard deviation. *p<0.05. 
 
 
 
The impact of fiber bundle length was evaluated by comparison of Device 1 and 2. With 
impeller configuration 2, Device 1 was found to be significantly greater than Device 2 (p<0.05), 
but no difference was found when comparing each Device with impeller configuration 1. Total 
differences in gas exchange at each rotation speed for impeller configuration 2 were small 
however, with a maximum range of 6.6 mL/min (12%). Comparisons of only the maximum gas 
exchange rates (57-60 mL/min) of each device were insignificant (p>0.05), indicating that no 
practical performance advantage is gained by modification of the total bundle length. 
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5.3.4 Impeller Effects 
Each device was evaluated with both impeller configurations (4 cm impeller length, 0.8 cm gap 
versus 1 cm impeller length, 0.2 cm gap). Impeller configurations were found to impact the 
performance curves in each device, where configuration 1 was superior in Devices 2 and 3, and 
configuration 2 achieved greater CO2 removal in Device 1 (each p<0.05). No impeller 
configurations yielded significantly different maximum CO2 removal rates however, so the 
overall impact of each difference was inconsequential.  
5.3.5 In Vitro Hemolysis 
Gas exchange performance was highest in Device 3 (30 cm length, 14.4 mm bundle diameter) 
and was selected for hemocompatibility testing. Maximum performance was comparable 
between impeller configurations, so each of the three prototypes were built with configuration 1 
(4 cm length, 0.8 cm gap) for ease of fabrication. Measured rates of pfHb accumulation were 
highly linear over testing periods (Δ𝑝𝑓𝐻𝑏 versus elapsed time R2 > 0.95 in all tests, results not 
shown). Table 5.3 shows the calculated hemolysis indices for the ULFED (at 4,000 PRM) and 
the control device. NIH values for the standard-ULFED circuit (0.78 ± 0.19 g/100L), dialysis-
ULFED circuit (1.55 ± 0.03 g/100L), and the control circuit (0.11 ± 0.01 g/100L) each differed 
significantly from one another (ANOVA p<0.001, all group-wise comparisons p<0.001). The 
TIH value of the standard-ULFED (0.190 ± 0.041 g/100min) did not differ significantly from the 
control circuit (0.123 ± 0.013 g/100min; Welch test p<0.001, group-wise p=0.169). The 
hemolysis using dialysis circuit components (0.386 ± 0.010 g/100min) was significantly greater 
than both other test groups (each p<0.05).  
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Table 5.3. Summary of ULFED in vitro hemolysis testing. 
Test Device 
Blood Flow TIH NIH 
(L/min) (g/100 min) (g/100 L) 
 ULFED (standard configuration) 0.25 0.190 ±0.041 0.775 ±0.186* 
 ULFED (dialysis configuration) 0.25 0.386 ±0.010* 1.551 ±0.025* 
 Minimax 1.25 0.123 ±0.013 0.105 ±0.012* 
 *Significant at p<0.05 versus all other devices 
 
5.4 DISCUSSION 
Supplementing respiration by removing CO2 independent of the lungs can improve outcomes for 
patients at risk of requiring or already receiving invasive mechanical ventilation. The ultra-low-
flow ECCO2R device (ULFED) operates at blood flow rates consistent with renal hemodialysis 
to simplify circuit management and minimize invasiveness of CO2 removal. In vitro CO2 
removal rates up to 74 mL/min at 4,000 RPM were achieved by the ULFED with minimal cell 
trauma (therapeutic index of hemolysis, TIH = 0.19 g/100min) at blood flows consistent with 
dialysis (250 mL/min). 
CO2 removal systems used in conjunction with non-invasive or protective ventilation 
strategies have been shown to correct pCO2 and pH in hypercapnic patients with removal rates 
equivalent to ~25-35% of the metabolic CO2 production (~200-250 mL/min) [53, 54]. CO2 
removal at these levels prevented intubation in patients with ae-COPD failing or unresponsive to 
non-invasive ventilation [3, 66, 72, 77]. Partial respiratory assistance has also aided weaning 
from ventilation [3, 126, 127] and allows reduction of ventilator tidal volumes to ultra-protective 
levels (3-4 mL/kg) [23, 128, 129]. The ULFED exceeded these CO2 removal rates by eliminating 
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~30-37% of the metabolic CO2 production at normocapnic test conditions (inlet pCO2 = 45 
mmHg). Gas exchange will also increase proportionally with pCO2 in hypercapnic patients, 
where CO2 removal up to 50% or more of metabolic production can be required.  
Efficient gas exchange in the ULFED minimizes necessary fiber surface area and enables 
clinically significant CO2 removal rates at hemodialysis blood flows. Pump-less arteriovenous 
CO2 removal (AVCO2R) requires dual cannulation (13-19 Fr) for circuit flows of 600-2,000 
mL/min that is shunted between the femoral artery and vein through a 1.3 m2 oxygenator [129, 
139, 140]. A newer integrated pump-oxygenator system uses a rotating core to generate active 
mixing to improve gas exchange up to 60% with a 0.59 m2 bundle [141]. Comparatively lower 
flows (350-500 mL/min) are possible in the simplified veno-venous circuit, but requires 15.5 Fr 
cannulation [22]. Developing systems combine existing oxygenators with dialysis controllers 
targeting even lower flows (200-300 mL/min) to minimize cannulation invasiveness (≤14 Fr). 
These systems utilize larger surface area gas exchangers (≥1 m2) to improve performance [77, 
78] or target lower CO2 removal using smaller pediatric oxygenators (40-55 mL/min with 0.3 m
2 
bundle in pigs with PaCO2 > 80 mmHg) [80]. Approaches to enhance CO2 removal such as 
bicarbonate dialysis [90], blood acidification [87], electrodialysis [88], plasma recirculation [73], 
and fiber enzyme coatings [84] are also being explored to reduce necessary blood flows for 
treatment. 
The rotating impellers in the ULFED enhance gas transfer by generating an active mixing 
effect in the fiber bundle that improves convective mixing at gas exchange surfaces [5, 44, 91, 
130]. Computational simulations have indicated development of continuously recirculating flow 
pathways in/out of the fiber bundle with impeller mixing [91]. Blood is pumped radially outward 
through the bundle by impellers, then pulled back into the bundle toward low-pressure regions in 
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the gaps between impellers before converging onto the impeller blade and cycling through the 
bundle again. Increasing flow velocity past gas exchange surfaces is a well-established 
mechanism for improving transfer efficiency by diminishing the thickness of the surface 
diffusive boundary layer [103]. This facilitates replenishment of gases to the membrane surface 
to maximize the concentration gradients spanning fiber walls. Recirculating flow also maintains 
a high level of washing in the bundle that eliminates regions of stagnation where thrombus 
formation may otherwise occur at low blood flows.    
The linear region of gas exchange performance at higher RPM that is observed in nearly 
all devices suggests there may be a maximum CO2 removal rate achievable by active mixing that 
is characteristic of the bundle geometry. This is supported by performance curves of each device 
being statistically distinguishable when comparing impeller lengths (each p<0.05), but ultimately 
achieving the same maximum CO2 removal rates (each p>0.05). Impeller length may have a 
stronger impact on gas exchange than demonstrated here, but the ability to establish this was 
limited by bundle geometry. 
We attribute the performance improvement between Device 1 and 3 here to the difference 
in bundle diameter, however the impeller geometry is different in these devices as well. The vane 
height of impellers in Device 3 are approximately 1/2 that of Device 1 impellers, which is 
necessary to accommodate the reduced inner diameter of the fiber bundle. It is unlikely the 
performance differences are associated with impeller vane height based on our previous findings 
using impellers for active mixing and mechanics of impeller mixing. Trimming vane height 
reduces overall impeller diameter, which reduces the blade tip velocity (and associated exiting 
fluid velocity) for any given rotation speed. We have also shown that increasing vane height (by 
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135%) of geometrically similar impeller designs by reducing drive shaft diameter improved gas 
exchange by <10% [5, 91].  
Simulations were conducted for each of the three ULFED device geometries to predict 
CO2 removal under passive flow conditions (i.e. 0 RPM). The computational analysis was 
conducted to support the hypothesis that impeller generated active mixing enhances CO2 removal 
rather than solely attributing increased CO2 removal to development of uniform flow in the fiber 
bundle. The results are presented as supportive evidence, but model predictions were not verified 
experimentally. Results of the analysis are shown in Table 5.4. Estimated 𝑉𝐶𝑂2 for each Device 
are compared to the measured maximum CO2 removal rate for each device listed as percent 
difference, i.e. Active Mixing % Enhancement = (measured 𝑉𝐶𝑂2,𝑚𝑎𝑥 𝑠𝑝𝑒𝑒𝑑
∗  – predicted 
𝑉𝐶𝑂2,0 𝑅𝑃𝑀)/(predicted 𝑉𝐶𝑂2,0 𝑅𝑃𝑀). Predictions were made using Reynolds coefficients that best 
represent the bundle geometry (𝑎 = 0.54, 𝑏 = 0.42) as well as conservative values that 
maximized predicted performance (𝑎 = 0.71, 𝑏 = 0.32). CO2 removal estimates differed by <5% 
between devices for each set of Reynolds coefficients. The representative and maximum CO2 
removal rates predicted were 40.1 ± 1.0 mL/min and 53.6 ± 0.9, respectively. This suggests that 
improved flow uniformity in the bundle at low rotation speeds only partially accounts for the 
increasing performance with rotation speed. Comparing model to experimental performance, we 
predict that active mixing in the ULFED contributes to an estimated 10–50% enhancement in 
Devices 1 and 2, and 40–80% enhancement in Device 3. 
The measured rate of hemolysis in the standard-ULFED circuit was comparable to a 
clinically approved oxygenator circuit. Two indexes of red cell trauma are reported here that 
indicate the rate of pfHb accumulation over time, the key difference being how time is reported. 
A major limitation of the NIH calculation is that hemolysis is normalized for blood flow rate, but 
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operating flow rate is ultimately irrelevant. Two systems intended for use at 5 L/min versus 0.25 
L/min that cause equivalent rates of total cell damage would differ in NIH by a factor of 20, 
despite returning an equal number of pfHb species to a patient. As a result the NIH calculation is 
bias against low-flow devices. The TIH calculation removes the flow rate normalization and 
provides a clinically relevant time-of-therapy rate of hemolysis. The limitation of both indices 
however is that no reliable benchmark threshold values have been validated for low-flow devices 
against in vivo performance to our knowledge. More information or in vivo testing is therefore 
necessary to make conclusions regarding acceptability of the dialysis-ULFED performance. No 
difference in hemolysis was observed between the control and standard-ULFED circuits, so we 
expect in vivo hemolysis to be acceptable in this configuration.   
 
 
 
Table 5.4. Predicted ULFED performance for each set of Re coefficients in Equation 5.6. 
ULFED Design 
0.54𝑅𝑒0.42  0.71𝑅𝑒0.32 
Predicted 𝑉𝐶𝑂2 Active Mixing  Predicted 𝑉𝐶𝑂2 Active Mixing 
(0 RPM) % Enhancement  (0 RPM) % Enhancement 
 Device 1 39 mL/min 48%  53 mL/min 10% 
 Device 2 40 mL/min 50%  53 mL/min 12% 
 Device 3 41 mL/min 82%  55 mL/min 37% 
 
 
 
Additional shortcomings of the NIH calculation are highlighted by the Minimax circuit 
performance. The NIH value of 0.105 ± 0.012 g/100 L is twice the generally accepted threshold 
(0.05 g/100 L) for tolerable hemolysis, despite each of the circuit components being approved 
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clinically. NIH values of approved adult oxygenator circuits have been reported up to 0.047 
g/100 L at a blood flow rate of 5 L/min [142]. This translates to an absolute rate of hemolysis 
almost twice that of the Minimax circuit reported here, further exemplifying the ambiguity of 
normalizing by blood flow rate. 
The simplicity of using the TIH calculation is further emphasized when considering the 
physiological pathway of plasma free hemoglobin clearance from the body. Conjugation of pfHb 
to haptoglobin allows clearance primarily through the reticuloendothelial system at plasma 
concentrations up to 130-150 mg/dL [105, 106]. Above these levels hemoglobin deposits into 
body tissues, hemoglobinuria occurs, and can eventually lead to endothelial cytotoxicity and 
excessive nitric oxide scavenging [107–109]. Bernstein et al. demonstrated in dogs that the 
haptoglobin clearance pathway sufficiently managed continuous infusions of 0.1 mg Hb/kg/min 
for three weeks without complications or plasma concentrations exceeding 100 mg/dL [143]. 
This infusion rate is equivalent to 0.7 g/100min in a 70 kg human, far exceeding hemolysis 
measured in either ULFED circuit configuration.  
Additional in vitro hemocompatibility testing could be conducted in future ULFED 
prototypes that focus on platelet adhesion and activation levels. Thrombus formation was 
qualitatively determined to be minimal after disassembly and inspection of ULFED prototypes 
following blood testing. Coagulation in the ULFED could form as a result of platelet activation 
in response to non-biologic surface contact or platelet cell lysis [120]. Fiber materials used in the 
ULFED were chosen partially to minimize biologic responses as demonstrated in previous 
oxygenator devices, but surface effects are still possible [97]. Verification that coagulation is 
minimal in the ULFED without excessive anticoagulation is valuable to support conclusions 
regarding safety. Platelet deposition rates on surfaces in future ULFED prototypes can be 
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quantified through plasma lactate dehydrogenase (LDH) levels and electron microscopy to 
identify thrombus networks on fiber surfaces or between fiber layers [8, 122].  
Future work may also focus on in vivo validation of benchtop performance or 
improvements to the ULFED aimed at simplifying the design, such as sealing the blood 
compartment with a magnetically coupled driveshaft that would obviate the driveshaft seal and 
saline infusion. Improvements to the housing design that were not thoroughly investigated here 
may also be investigated. The gap distance between the housing wall and fiber bundle could be 
revisited, enabling priming volume to be reduced by up to 30%. Future ULFED bundles could be 
shortened to reduce priming volume and materials after bundle length was shown to have no 
impact on gas exchange. Incorporation of carbonic anhydrase (CA) immobilized fibers may 
enhance gas exchange and improve biocompatibility [6–8]. CA fibers in an active mixing device 
is explored further in Chapter 6.0. 
 103 
6.0 CARBONIC ANHYDRASE WITH ACTIVE MIXING FOR LOW FLOW CO2 
REMOVAL ENHANCEMENT 
6.1 INTRODUCTION 
The use of bioactive carbonic anhydrase (CA) immobilized fibers has been demonstrated in 
miniaturized gas exchange modules to increase CO2 removal performance by up to 37% in blood 
[84]. CO2 removal enhancement with CA fibers diminished as the flow rate in the modules 
increased, suggesting that devices with longer transit times (i.e. low flow rate) would benefit the 
greatest from the technology [84]. Additional mechanisms that reduce the diffusional boundary 
layer resistance without affecting device transit time such as active mixing should also promote 
delivery of bicarbonate to the boundary layer. A low-flow active mixing CO2 removal device 
such as the ULFED could therefore benefit significantly from the CA fiber technology. 
To evaluate the feasibility of combining the CO2 removal enhancements of active mixing 
and CA immobilized fibers in a meaningful way, Bioactive CA fibers were incorporated into a 
modified ULFED prototype to evaluate the feasibility of improving CO2 removal versus either 
approach independently. In vitro gas exchange tests were conducted with a CA-ULFED 
prototype and control devices at low blood flow rates (250 mL/min). 
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6.2 METHODS 
6.2.1 Device Fabrication 
The device used for evaluating CA with active mixing (Figure 6.1) was designed with 
comparable geometry to the ULFED feasibility prototype described in Section 4.2.1. The design 
of the CA-ULFED devices differ only in the length of the fiber bundle and the type of fibers 
used. PP fibers were swapped for wetting-resistant polymethylpentene (PMP) (380 μm outer 
diameter, Membrana Oxyplus, Wuppertal, Germany) fibers to eliminate concerns associated with 
hydrophobicity losses through the immobilization process. The blood compartment length of the 
prototype was reduced to 9.3 cm due to the availability of shortened PMP fibers. Bundle 
permeance in the modified ULFED using larger diameter PMP fibers was matched to the PP 
bundle in other ULFED designs to replicate active mixing conditions. The final CA-ULFED was 
designed with bundle porosity = 0.56 and 523 fibers, for total surface area 0.058 m2. Device 
assembly was otherwise consistent with the techniques described in Section 4.2.1 with the 
exception of the fiber potting adhesive. A waterproof epoxy (Anchor-Tite Superglue; Pacer 
Technology, Ranchero, CA, USA) was used for potting fibers to allow fibers to remain hydrated 
during potting. A flexible driveshaft was fitted with 7 impellers (Crescent geometry, 3 vanes, 2 
mm shaft spacing). All other components and dimensions used in the modified ULFED matched 
those described in Section 4.2.1. Six prototypes were fabricated and tested for gas exchange (n=2 
for three fiber test groups).  
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Figure 6.1. Mini-ULFED prototype with CA fibers in blood gas exchange loop. 
 
 
 
6.2.2 Fiber Preparation & Assays 
CA was immobilized to chitosan groups bound to surface amine groups on PMP fibers. The fiber 
immobilization protocol was initially developed and tested on siloxane-coated PP fiber [84], but 
adapted here for PMP fibers. PMP fibers were cleaned and aminated by plasma-enhanced 
chemical vapor disposition (PECVD) using an ION 40 plasma chamber (PVA Tepla, Corona, 
CA, USA). The number of available binding sites for CA immobilization were increased by 
treating aminated fibers with 5% glutaraldehyde in 100mM phosphate buffer (8.5 pH) followed 
by 1% chitosan (chitosan 448869; Sigma Aldrich, St. Louis, MO, USA) in 1% acetic acid to 
cross-link chitosan to surface groups. Residual chitosan non-covalently bound was cleaned from 
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fibers with a deionized water rinse. Fibers were left overnight in a bovine CA solution (1 mg/mL 
in 100 mM 8.5 pH phosphate buffer) (carbonic anhydrase C3934; Sigma Aldrich, St. Louis, MO, 
USA) after a second glutaraldehyde treatment to bind CA to chitosan activated amine groups.  
Surface amination following chitosan binding on PMP fibers was quantified with a 
Sulfosuccinimidyl-4-0-(4,40-dimethoxytrityl) butyrate (sulfo-SDTB) colormetric amine assay 
(M109; ProChem Inc., Rockford, IL, USA) [144]. An NHS moiety in the sulfo-SDTB first binds 
to surface amine groups. A colormetric group on the sulfo-SDTB is then cleaved from bound 
molecules using perchloric acid after solution is rinsed away. Supernatant fluid is then quantified 
spectrophotometrically at 498 nm. Concentration was calculated from a standard curve generated 
with serial dilutions of sulfo-SDTB stock solution in 35% perchloric acid.   
Carbonic anhydrase activity levels were measured using an esterase activity by 
monitoring the rate of hydrolysis of p-nitrophenyl acetate (p-NPA) to p-nitrophenol (p-NP). 
Activity was measured under both passive and shearing flow conditions. Passive flow testing 
followed the assay protocol verified previously and results were compared to reported activity 
levels for fibers used for gas exchange in earlier studies [84]. Activity was quantified prior to 
blood testing spectrophotometrically every 1 minute for 6 minutes at 412 nm in 114 fiber mats 
aminated and immobilized in parallel with the 523 fiber CA-ULFED mats. Mats were rolled and 
inserted into a 15 mL recirculating loop of 100 mM phosphate buffer 7.5 + 80 μM p-NPA at 45 
mL/min. One activity unit is defined as the amount of CA necessary to hydrolyze 1 μmol p-NPA 
per minute. Assays were repeated for each mat (n=3) and the average of each is reported.  
 Shearing flow activity levels were measured to evaluate the non-permanent effects of 
active mixing on immobilized CA (e.g. possible conformational changes affecting catalytic rate 
in shearing flow). Fiber mats used in passive flow activity assays were potted into complete 
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mini-ULFED prototypes to replicate active mixing conditions of gas exchange devices. Activity 
was measured over 10 minutes at 2 minute increments in 60 mL recirculating loops of 100 mM 
phosphate buffer 7.5 + 80 μM p-NPA. Two control and two CA devices were tested from 0-
30,000 RPM at 10,000 RPM increments. A fifth test device containing no fibers was fabricated 
to control for the effects of shearing flow on p-NPA independent of fibers. Measurements were 
replicated (n=2) at each rotation speed.  
6.2.3 Gas Exchange Testing 
CO2 removal testing was conducted in a recirculating gas exchange loop as described in Section 
4.2.2 using similar methods for blood collection, anticoagulation, and gas exchange 
measurements. Three fiber types were evaluated in mini-ULFED prototypes (untreated control 
fibers, chitosan immobilized control fibers, and CA immobilized fibers) for a total of six devices 
(n=2 of each). Gas exchange was measured at 10,000 RPM increments from 0-30,000 RPM, with 
a minimum of two measurements at each speed. Pure O2 sweep gas was maintained at 3.0 L/min 
for all measurements to minimize potential variability between devices. A 0 RPM measurement 
was repeated after each rotation speed in the CA-fiber devices to validate that performance did 
not vary from baseline. Variance from baseline with repeated 0 RPM measurements may indicate 
permanent damage to immobilized CA.   
Average device performances at minimum (0 RPM) and maximum (30,000 RPM) speeds 
were compared statistically in SPSS (PASW Statistics 18; IBM, Armonk, NY). One-way 
ANOVA with post-hoc Tukey t-tests were conducted for each rotation speed to evaluate the 
hypothesis that CA-fiber performance is greater than each control group. Appropriateness of 
parametric statistical comparisons was verified by testing assumptions of homogeneity of 
 108 
variance and normality with Levene’s test and Kolmogorov-Smirnov tests, respectively. 
Significance was accepted at the level of p<0.05.  
6.3 RESULTS 
6.3.1 Fiber Amine Density and Activity Assays 
Results of the amine density assays are shown in Figure 6.2. Amine density of chitosan fibers 
(2.78 ± 0.52 nmol/cm2) were significantly greater (p>0.05) than untreated PMP control fibers 
(0.04 ± 0.008 nmol/cm2). This level of amination is comparable to surface densities reported by 
Kimmel et al. used for CA immobilizations and subsequent gas exchange testing [8].  
 
 
 
 
Figure 6.2. Average amine density on chitosan immobilized fibers versus control fibers.  
Chitosan data represents the average of two separate immobilizations corresponding to each 
mini-ULFED device tested in blood. Error bars represent one standard deviation. 
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Activity levels for passive flow activity assays are shown in Figure 6.3. Sample fiber 
mats from both immobilization had activity levels >0.005 μM/min/cm2 under passive flow 
conditions. CO2 removal rates from PBS were measured on these fibers (data not shown) under 
passive flow conditions to verify that percent enhancement versus control was consistent with 
previous work [84].  
 
 
 
 
Figure 6.3. Immobilized carbonic anhydrase activity levels on mini-ULFED PMP fibers. 
Activity level is the average of repeated assays (n=3) on the same fiber set. Error bars represent 
one standard deviation. 
 
 
 
Measured activity levels of the same 114 fiber mats under shearing flow are shown in 
Figure 6.4. Activity is reported as the average and standard deviation between two devices at 
each rotation speed. Fiberless control data is reported as average and standard deviation of 
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activity in one test with repeated measurements since only one device was fabricated. Average 
activity of the CA devices was significantly greater than the control devices (untreated fibers and 
fiber-less) at each rotation speed. This provides evidence that impeller generated flow and 
associated shear does not have a transient deactivation effect on immobilized CA enzyme. 
Overall activity levels in the CA device were lower than associated passive flow tests however 
the devices differ in geometry and this was anticipated. As rotation speed increased the apparent 
activity level increased by over 50% at 30,000 RPM versus passive (0 RPM) conditions in the 
CA device. This observation could indicate that CA activity becomes more active under shearing 
flow, but similar behavior in each of the control devices suggest this may be an artifact of the p-
NPA assay. 
 
 
 
 
Figure 6.4. Mini-ULFED activity levels under shearing flow conditions. Error bars represent one 
standard deviation. 
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6.3.2 In Vitro Gas Exchange 
Normalized CO2 removal rates achieved in each test group are shown in Figure 6.5 as total 
performance of each device (left) and as percent enhancement at each rotation speed versus the 
untreated control fibers (right). Statistical analysis was conducted at minimum and maximum 
rotation speeds. At 0 RPM, CA was found to enhance CO2 removal by 9% and 14% versus 
untreated control fibers and chitosan fibers (ANOVA with post-hoc Tukey test p<0.05) whereas 
no statistical difference was determined between chitosan and untreated fibers (p>0.05). At 
maximum speed, no statistical difference was found between any groups (ANOVA p=0.94). CA 
outperforming each control device at 0 RPM was anticipated, verifying the benefits of CA fibers 
under passive flow conditions as was shown previously [8, 84]. Chitosan fiber performance 
increased 63% from 0 RPM to 30,000 RPM, comparable to the 59% increase measured with 
untreated fibers and statistically indistinguishable at each rotation speed. In contrast, CA fiber 
performance increased by an average 44% for a maximum CO2 removal rate within 2% of that 
achieved by the control devices.   
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Figure 6.5. CO2 Removal rate of CA-ULFED and controls versus rotation speed. (left) Total 
CO2 removal rates of each test group (two devices each) versus rotation speed. (right) CO2 
removal performance of CA and chitosan fiber devices as percent enhancement versus control 
(untreated) fibers at each rotation speed. 
 
6.4 DISCUSSION 
Carbonic anhydrase enzyme fiber coatings have been shown to enhance CO2 removal 
performance in low-flow artificial lung devices. PMP hollow fiber membranes were immobilized 
with CA using established methods and incorporated into a mini-ULFED to investigate the 
combined effects of active mixing and enzyme approaches. CA coated fibers were found to 
improve CO2 removal by 9% under passive flow (0 RPM) conditions, but contributed to no 
additional gas exchange at the maximum rotation speed tested.  
CA fibers offer a simplified approach to enhance CO2 removal in low-flow devices. Use 
of CA fibers adds minimal bedside complexity to CO2 removal systems and was shown to reduce 
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platelet deposition rates versus heparin control fibers [122]. Several other approaches to improve 
CO2 removal are in development that use additional circuit components to continuously modify 
blood pH or electrolyte concentrations. Adding acidic species to whole blood or sweep gas has 
been explored to push the equilibrium of CO2/bicarbonate ion toward CO2 and increase blood 
pCO2 [85–87]. This increases the partial pressure gradient driving CO2 diffusion through fiber 
walls and increases gas transfer rates. Whole blood acidification with continuous lactic acid 
infusion increased CO2 removal up to 78% in pigs [87]. Addition of small amounts of sulfur 
dioxide (SO2) to sweep gas increased CO2 removal by 17% in vitro, but synergistically enhanced 
CO2 removal when combined with CA fibers by improving gas exchange by 109% [85]. Blood 
electrodialysis was shown to double CO2 removal at 250 mL/min blood flow in pigs [88]. 
Further testing is necessary to assess the impact on renal function after ion concentrations were 
affected and required correction during treatment however. Direct elimination of bicarbonate ion 
from blood was also investigated by removing ultrafiltrate containing bicarbonate and replacing 
it sodium hydroxide replacement solution [90]. An average of 60 mL/min of CO2 was removed 
in bicarbonate dialysis when ultrafiltrate was replaced at 100-150 mL/min.  
Carbonic anhydrase is a native enzyme localized to erythrocytes that catalyzes the 
reversible hydration of CO2 into carbonic acid that subsequently dissociates to bicarbonate ion. 
Through this reaction the CO2 carrying capacity of blood is significantly increased, where >90% 
of CO2 is in the form of bicarbonate or bound to hemoglobin [6, 33]. Physiologically this 
reaction is utilized for blood buffering but presents challenges for artificial lung operation by 
maintaining low CO2 partial pressures in the blood. The relatively low pCO2 gradient between 
blood and sweep gas limits pressure gradients driving diffusion of gas through the fiber 
membrane into the sweep gas as well as diffusion of CO2 gas to the surface boundary layer. 
 114 
Within the surface boundary layer dissolved CO2 is quickly depleted. CO2 replenishment is 
primarily dependent on the diffusion of additional CO2 from bulk flow due to the slow 
uncatalyzed dehydration of HCO3 to CO2 and low red cell concentration in the boundary layer. 
Replenishment of CO2 to the fiber surface slows as bulk pCO2 drops, causing disequilibrium of 
HCO3/CO2 in the boundary layer. In previous work we demonstrated that immobilizing CA 
enzyme directly to fiber surfaces increases CO2 removal efficiency by locally dehydrating 
bicarbonate ions to CO2 at gas exchange surfaces [6–8, 84]. Up to 37% increased CO2 removal 
from blood was achieved under passive flow conditions in miniaturized artificial lung modules. 
This effect was shown by Arazawa et al. to be most effective when disequilibrium in the 
boundary layer was greatest, i.e. when blood flow rate is minimized. In this work we 
hypothesized the contribution of CA coatings could be maximized when paired with conditions 
that reduce boundary layer thickness and promote HCO3/CO2 disequilibrium – conditions that 
align with objectives of the ULFED. Active mixing in the ULFED minimizes boundary layer 
thickness while low flows promote disequilibrium. By combining the demonstrated effects of 
impeller mixing in the ULFED with CA fibers we hypothesized the two technologies would 
complement each other, achieving greater CO2 removal rates than either independently.  
Gas exchange comparisons at 0 RPM are representative of passive flow conditions, so the 
higher removal rates measured in the CA device were anticipated. The percent enhancement 
under passive conditions was less than the 14-37% enhancement previously reported. The device 
geometry, flow pathways, and flow rate in the mini-ULFED differed enough that a reasonable 
prediction for passive flow conditions in our test device was not determined. Matching 
performances at the maximum rotation speed suggest that CA fibers do not increase gas 
exchange enhancement versus active mixing alone. 
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The mechanism explaining the finding that CA is ineffective versus active mixing alone 
is under investigation. Active mixing may cannibalize enhancement associated with CA fibers. 
Carbonic anhydrase coatings are thought to take advantage of disequilibrium within the 
boundary layer to locally convert HCO3 to CO2. Active mixing alternatively increases fluid 
velocity at the fiber surface to minimize the boundary layer thickness, reducing the diffusional 
distance for bulk CO2 to reach the fiber surface. At extreme fluid velocities the boundary layer 
thickness can be effectively negligible. In such a system bulk CO2 reaches the surface without 
diffusional resistance and immobilized CA competes with endogenous enzyme. This effect may 
not have been observed in passive flow modules due to the relatively low velocities versus an 
effective active mixing system.  
Shear effects from aggressive impeller flows may also transiently deactivate immobilized 
CA. Unfolding of proteins under shearing flow is well documented for blood enzymes and 
evidence exists that transient unfolding can occur [145, 146]. To our knowledge no formal 
evaluations have been conducted specifically to investigate transient shear effects on CA 
enzyme. This theory was evaluated by measuring activity levels of CA fibers versus control 
devices in modified ULFED with impeller mixing. CA fiber activity was significantly greater 
than control activity at all rotation speeds, contributing evidence that impeller mixing does not 
transiently deactivate CA. A limitation of this analysis however is that p-NPA hydrolysis to p-
NP by CA is dramatically slower than the corresponding bicarbonate/CO2 reaction. The rate 
constant for HCO3/CO2 (~1 × 10
6 s-1) is on the order of 1 million times greater than for p-NPA/p-
NP (~1 s-1) [147, 148]. Therefore measuring the slower p-NPA/p-NP reaction rate may not reveal 
a partial reduction in CA catalytic rate by shearing flow that affects HCO3/CO2 conversion. The 
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presented data here contributes evidence to the hypothesis that CA activity is preserved under 
shearing flow conditions, but limitations with the assay prevent fully supporting this conclusion.   
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7.0 SUMMARY AND CONCLUSIONS 
Mechanical ventilation has long been the first point of care for patients suffering from 
hypercapnic lung failure. Less invasive ventilation techniques have shown patient benefit, but 
low CO2 removal rates introduces new risks. Evidence continues to grow that extracorporeal CO2 
removal (ECCO2R) can effectively prevent intubation, facilitate earlier extubation, or allow 
reduction of ventilator settings in hypercapnic respiratory failure. ECCO2R systems exist but 
improvements to system complexity and invasiveness are necessary to mitigate risks associated 
with high blood flow rates. The objective of this project was to develop novel CO2 removal 
devices for clinically significant respiratory support that minimize invasiveness and simplify 
treatment.  
The impeller percutaneous respiratory assist catheter (IPRAC) is an intravascular device 
that reduces system complexity as it requires no external blood circuitry. The IPRAC was 
previously shown to achieve the greatest CO2 removal efficiency of any reported blood gas 
exchanger, with potential for further improvement through impeller design optimization. The 
effects of impeller spacing, number of vanes, and blade design were investigated with the 
objective of achieving CO2 removal to 25-35% of the metabolic CO2 production. We also 
targeted a reduction of the insertion diameter from 25 Fr to <20 Fr to minimize invasiveness. 
Reducing the spacing between impellers to allow additional impellers on the shaft was found to 
improve CO2 removal rates, but all other effects were found to insignificantly affect 
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performance. Overall improvement in CO2 removal performance was ~10% and maximum CO2 
removal rates of 15-20% metabolic CO2 production was achieved.  
Hemocompatibility studies were subsequently conducted with the IPRAC to establish the 
safety of impeller generated active mixing. Hemolytic contribution of the rotating impellers, 
fiber bundle, impeller/cage interactions, and surface finish (roughness) were systematically 
evaluated through in vitro hemolysis studies. Contact between rotating impellers and the 
surrounding safety coil was found to exacerbate cell damage, but this effect may be alleviated 
through surface treatments of impellers (polishing). Each other design component was found to 
insignificantly contribute to hemolysis, indicating the rotating impeller approach can be used 
safely in devices that may benefit from active mixing.  
The rotating impeller technology was adapted for use in an extracorporeal artificial lung 
device. The objective of the ultra-low-flow ECCO2R device (ULFED) was to improve upon 
existing ECCO2R technologies by minimizing invasiveness and simplifying circuitry. Circuit 
blood flow rates on the order 250 mL/min are comparable to renal hemodialysis, and would 
enable use of patient connection strategies used for dialysis. Similar patient management 
strategies and circuity between dialysis and ECCO2R indicate potential for use of the ULFED 
directly with existing hemodialysis circuitry or with a hemodialysis machine. Removing CO2 
equivalent to 25-35% metabolic production at hemodialysis blood flows was demonstrated with 
a prototype modeled from the IPRAC. During feasibility testing an ULFED prototype achieved 
CO2 removal of 75.3 mL/min at the target 250 mL/min blood flow rate. Identification of 
components that contributed to hemolysis and design features unnecessary for an extracorporeal 
device motivated a redesign of the ULFED prototype to tailor it for extracorporeal use.  
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A larger diameter ULFED prototype was designed to accommodate a rigid driveshaft that 
eliminated impeller/cage contact and allowed investigation of previously unexplored design 
features. A suitable range of device dimensions for the ULFED was determined using a 
theoretical critical rotation speed analysis. Additional design features previously uninvestigated 
in the IPRAC that may impact gas exchange were also evaluated (bundle aspect ratio and 
number of flow recirculation regions in the bundle – i.e. number of impellers). Bundle diameter 
was found to affect gas exchange performance where a reduction in the fiber bundle diameter 
improved gas exchange by ~30% versus other larger diameter prototypes. Length of the fiber 
bundle and the number of recirculation regions in the bundle were found to insignificantly affect 
total gas exchange. The CO2 removal rate in the redesigned ULFED reached 74 mL/min (30-
37% metabolic production) at 4,000 RPM and 250 mL/min blood flow.  
Hemolysis studies were conducted with the top performing ULFED using both ECCO2R 
circuit components (centrifugal blood pump and ECMO cannula) and hemodialysis circuit 
components (roller pump and dialysis cannula). The time-of-therapy normalized rate of 
hemolysis (therapeutic index of hemolysis, TIH) using ECCO2R components was not statistically 
distinguishable from a control loop consisting of approved components. Hemolysis is therefore 
expected to be acceptable in vivo for the ULFED in this configuration. Hemolysis rates were 
higher using dialysis circuit components, however a reliable threshold for in vitro hemolysis for 
low-flow devices has not been established. The ULFED was shown to eliminate clinically 
significant levels of CO2 from blood with acceptable hemolysis at hemodialysis blood flows, 
making minimally invasive dialysis connection strategies and simplified management possible 
for ECCO2R. 
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Hollow fiber membranes with surface immobilized carbonic anhydrase have been shown 
to effectively enhance CO2 removal rates from blood, with the most promising application being 
low-flow active mixing devices. Miniaturized ULFED prototypes were fabricated with CA 
immobilized fibers and evaluated for gas exchange. CA fibers together with active mixing may 
facilitate development of devices that can be miniaturized, operate at lower blood flows, at 
reduced rotation speeds, or achieve higher total gas exchange. These improvements could 
improve hemocompatibility, simplify treatment, or improve marketability of the ULFED. CO2 
removal rates under passive flow conditions (0 RPM) verified previous test results, however no 
significant difference was found between control and CA fibers as rotation speed increased.  
7.1 FUTURE VISIONS 
Among all concepts explored for partial support an intravascular device in theory may be the 
most attractive for respiratory assistance. Elimination of external circuitry and a blood pump 
reduces risks associated with blood outside the body, simplifies device management, and 
minimizes blood contacting surface area. Challenges for all intravascular devices remain 
achieving clinically significant gas exchange rates with a minimally invasive form factor. Active 
mixing was demonstrated among respiratory assist catheters to generate the most efficient CO2 
removal rates but significant improvements are necessary to match total performance of new 
extracorporeal CO2 removal systems (ECCO2R). Recent advances in ECCO2R technology and 
wider recognition of the clinical need has increased competition in the market space. 
Competitive development in ECCO2R focused on reducing risks, invasiveness, and complexity 
has advanced the field more quickly than competing technologies for intravascular devices. The 
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benefits of an intravascular design still give the concept a competitive advantage however, given 
the potential advantages for simplified support. Future work on the IPRAC may focus on 
integration of additional technologies that independently improve CO2 removal. Demonstrated 
approaches feasible for an intravascular device such as adding fractions of acidic gas to fiber 
sweep gas could improve gas exchange if risks and challenges of such approaches are addressed. 
Other approaches that would enhance performance may include design improvements that allow 
higher surface areas without impacting insertion diameter. A collapsible impeller/cage assembly 
would allow expansion of a low-diameter device in situ. A design for two-stage insertion could 
also allow for placement of a packed fiber bundle that is later expanded by the impeller/cage 
assembly. Future intravascular technologies that improve or combine existing approaches for 
enhancing CO2 removal, or development of new approaches would make respiratory assist 
catheters an attractive alternative to ECCO2R.    
Extracorporeal systems currently remain the most viable approach for simplified 
respiratory support. Growing competition to simplify systems and make attachment minimally 
invasive are pathways to wider clinical adoption, rather than limiting its use to ECMO centers. 
Most development in university research settings to enhance CO2 removal rates has resulted in 
systems that add complexity to therapy. Approaches such as blood acidification, electrodialysis, 
or bicarbonate dialysis require additional circuit components and require monitoring and/or 
adjustment of blood pH and ionic concentrations. Industrial development in CO2 removal has 
focused instead on approaches that simplify management with integrated systems and function 
similar to familiar therapies. The impeller technology and CA coating have an advantage over 
other CO2 removal approaches in development because they minimize bedside complexity with 
minimal impact on the patient or circuit management. Impellers add complexity comparable to a 
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blood pump that is adjusted only to impact CO2 removal rates, while CA enzyme coatings add no 
complexity to bedside systems. Demonstrating clinically significant gas exchange rates in the 
ULFED at operating conditions matching hemodialysis is a milestone in CO2 removal. 
Intensivists treating patients with respiratory issues are the same clinicians already familiar or 
comfortable with dialysis systems. This leads to potential adoption of minimally invasive 
dialysis cannulation strategies, direct use with dialysis equipment, or to splice ECCO2R directly 
into existing dialysis circuitry. Future developments of the ULFED system may focus on design 
improvements independent of the gas exchange system or achieving secondary design objectives. 
Magnetically coupling or levitating the impeller driveshaft would seal the blood compartment, 
eliminating the need for driveshaft seals and the saline infusion line. Features identified to 
impact gas exchange such as bundle aspect ratio could be optimized to reduce priming volumes 
or further reduce necessary blood flow rates for treatment. Further developments with the 
ULFED, CA enzyme, and competing technologies will help push respiratory assistance to close 
logistical gaps between respiratory and renal dialysis and encourage widespread adaptation.    
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